 CONFIDENTIAL  Protocol No. SP005  
  EudraCT: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page 1 of 96 
 
 
Clinical Development  
 
 
 
DCVAC/PCa  
 
 
Clinical Trial Protocol SP005   
 
 
A Randomized, Double Blind, Multicenter, Parallel -Group, 
Phase  III Study to Evaluate Efficacy and Safety of DCV AC/PCa 
Versus Placebo in Men with Metastatic Castration Resistant 
Prostate Cancer Eligible for 1st Line Chemotherapy  
 
 
 
Document type  Clinical Trial Protocol for Oncology  
EudraCT / IND number  EudraCT 2012 -002814 -38 / IND 015255  
Version number  V07.0 
Development phase  III 
Document status  Final  
Date 08Mar 2018 
 
 
 
Property of SOTIO a.s.  
 
Jankovcova 1518/2  
170 00 Prague 7  
Czech Republic  
 
(Hereinafter referred to as “Sponsor or SOTIO ”) 
 
 
 
CONFIDENTIAL  
This document contains proprietary information and trade secrets of SOTIO. This information may not be used, 
divulged, published, copi[INVESTIGATOR_781285].  
 
  
 CONFIDENTIAL  Protocol No. SP005  
  EudraCT: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page [ADDRESS_1074004] the study.  Documentation of my qualifications 
and professional affiliations are contained in my up -to-date curriculum vitae.  
I will provide the supplied copi[INVESTIGATOR_781286] -clinical and prior clinical 
experience (e.g. Investigator’s Brochure) to all staff in my unit who participate  in this study.  I will discuss this 
material with them to ensure that they are fully conversant with medical treatment and the conduct of the study, 
and tha t they will handle the data and information generated in the study confidentially.  
I will conduct the study in accordance with Good Clinical Practice, the Declaration of Helsinki, the study protocol 
and the moral, ethical and scientific principles that jus tify medical research.  The study will be conducted in 
accordance with the relevant laws and regulations relating to clinical studies and the protection of subjects of the 
country in which the study will be performed.  All subjects will be informed comprehen sively about the nature of 
the study and will give their written consent to participate before entry into the study.  They will be informed that 
they may withdraw from the study at any time.  I will use only an information sheet and consent form approved by 
[CONTACT_781319] ( IEC)/ Institutional Review Board (IRB)  which has reviewed this 
study.  I will supply SOTIO with any material written by [CONTACT_38788] (e.g. summary of study) which is given to the EC 
in support of the application.  
Where applicable and required the information contained in the case report forms will be transcribed from my 
records, reports and manuscripts.  The case report form may be the original source document for certain items. 
Either I or an appointed person will attest  to the authenticity of the data and accuracy and completeness of the 
transcription by [CONTACT_219486].  I agree to the audit and monitoring procedures that involve 
verification of study records against the original records by [CONTACT_781320].  Should it be requested by [CONTACT_781321], I will make available additional background data from my records, and where allowed from 
the hospi[INVESTIGATOR_219443].  I certify that any laboratory, excluding the centr al 
laboratory(s) appointed for the study in which laboratory parameters will be determined is subject to regular 
external quality control.  
I understand that the case report forms and other data pertinent to this study are the property of SOTIO and are 
confidential.  I will supply SOTIO with the study data in such a way that the subject normally cannot be personally 
identified.  
I consent to SOTIO’s and CRO’s collection, processing, transfer, use and storing of my personal data and details 
relating to my profe ssional activities for the purposes of the study.  
I understand that the study may be terminated or enrolment  suspended at any time by [CONTACT_1034], with or without 
cause, or by [CONTACT_17138].  
 
Investigator Signature:   __________________________________________________  
 
Date:     __________________________________________________  
 
Print Name:    __________________________________________________  
 
Address:    ________________________________________ __________  
 
Telephone Number:   __________________________________________________  
 
 
OTHER CONTACT [CONTACT_7533]:  
 
Full contact [CONTACT_781322], the Sponsor, and key coordinating and operational personnel 
involved in this clinical trial will be maintained in the Trial Master File and in each Site Study File.  
 CONFIDENTIAL  Protocol No. SP005  
  EudraCT: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page [ADDRESS_1074005] UDY PROTOCOL SYNOPSI S ................................ ..............................  14 
1 BACKGROUND  ................................ ................................ ................................ ..............................  21 
1.1 OVERVIEW OF PROSTATE CANCER  ................................ ................................ ............................  21 
1.2 IMMUNOTHERAPY IN PROSTATE CANCER  ................................ ................................ .................  22 
1.3 OVERVIEW OF DCVAC/PC A ................................ ................................ ................................ ...... [ADDRESS_1074006] OF CARE THERAPI[INVESTIGATOR_781287] M CRPC  ................................ ....................  27 
1.5 HISTORY OF AMENDMENTS  ................................ ................................ ................................ .........  27 
2 STUDY RATIONALE/PURP OSE  ................................ ................................ ................................ .. 30 
2.1 RATIONALE FOR CHEMO -IMMUNOTHERAPY  ................................ ................................ .............  30 
3 OBJECTIVES  ................................ ................................ ................................ ................................ .. 33 
3.1 STUDY OBJECTIVES  ................................ ................................ ................................ .....................  33 
3.2 STUDY ENDPOINTS  ................................ ................................ ................................ .......................  33 
3.2.1  PRIMARY EFFICACY ENDPOINT  ................................ ................................ ................................ .. 33 
3.2.2  SECONDARY EFFICACY ENDPOINTS  ................................ ................................ ...........................  33 
3.2.3  SAFETY ENDPOINTS  ................................ ................................ ................................ ....................  34 
3.2.4  EXPLORATORY ENDPOINTS  ................................ ................................ ................................ ........  34 
4 STUDY DESIGN  ................................ ................................ ................................ .............................  35 
5 POPULATION  ................................ ................................ ................................ ................................ . 37 
5.1 INCLUSION /EXCLUSION CRITERIA  ................................ ................................ .............................  37 
5.1.1  INCLUSION CRITERIA  ................................ ................................ ................................ ..................  37 
5.1.2  EXCLUSION CRITERIA  ................................ ................................ ................................ .................  38 
6 TREATMENTS  ................................ ................................ ................................ ...............................  40 
6.1 DESCRIPTION OF TREATMENTS  ................................ ................................ ................................ .. 40 
6.1.1  STUDY DRUG /PLACEBO  ................................ ................................ ................................ ..............  [ADDRESS_1074007] OF CARE THERAPI[INVESTIGATOR_5165]  ................................ ................................ ................................  40 
6.2 HOW THE STUDY DRUG IS SUPPLIED  ................................ ................................ ..........................  41 
6.2.1  STUDY DRUG /PLACEBO  ................................ ................................ ................................ ..............  [ADDRESS_1074008]: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page [ADDRESS_1074009] OF CARE THERAPI[INVESTIGATOR_5165]  ................................ ................................ ................................  42 
6.3 STORAGE , PREPARATION AND ADMINISTRATION  ................................ ................................ ..... 42 
6.3.1  DCVAC/PC A / PLACEBO  ................................ ................................ ................................ ............  [ADDRESS_1074010] OF CARE THERAPI[INVESTIGATOR_5165]  ................................ ................................ ................................  42 
6.4 PATIENT NUMBERING  ................................ ................................ ................................ ..................  43 
6.5 TREATMENT ASSIGNMENT  ................................ ................................ ................................ ..........  43 
6.6 TREATMENT BLINDING  ................................ ................................ ................................ ...............  43 
6.7 PATIENT TREATMENT SEQUENCE  ................................ ................................ ..............................  44 
6.7.1  SCREEN /RANDOMIZE  ................................ ................................ ................................ ..................  [ADDRESS_1074011] OF CARE CHEMOTHERAPY PLU S DCVAC/PC A OR PLACEBO AND 
CONSEQUENTLY WITH DCVAC/PC A OR PLACEBO ALONE  ................................ ................................ .... 45 
6.8 ANCILLARY TREATMENTS  ................................ ................................ ................................ ..........  46 
6.8.1  ANDROGEN DEPRIVATION THERAPY  ................................ ................................ ..........................  46 
6.8.2  RESCUE MEDICATION  ................................ ................................ ................................ .................  46 
6.8.3  OTHER CONCOMITANT MED ICATIONS  ................................ ................................ ........................  46 
6.8.4  PROHIBITED MEDICATIONS  ................................ ................................ ................................ ........  46 
6.9 PERMITTED DOSING MODIFICATIONS ................................ ................................ ........................  47 
6.10  STUDY DRUG DISCONTINU ATION /END OF TREATMENT  ................................ ..........................  47 
6.11  FOLLOW -UP FOR TOXICITIES  ................................ ................................ ................................ .... 48 
6.12  FOLLOW -UP FOR SURVIVAL  ................................ ................................ ................................ ...... 48 
6.13  PREMATURE PATIENT WIT HDRAWAL / END OF STUDY  ................................ ...........................  48 
6.14  EMERGENCY UNBLINDING OF TREATMENT ASSIGNM ENT ................................ .......................  49 
7 VISIT SCHEDULE AND A SSESSMENTS  ................................ ................................ ...................  50 
7.1 PATIENT DEMOGRAPHICS /OTHER BASELINE CHARACTERISTICS  ................................ ...........  55 
7.2 TREATMENTS  ................................ ................................ ................................ ...............................  56 
7.3 EFFICACY  ................................ ................................ ................................ ................................ ..... 56 
7.3.1  PROSTATE -SPECIFIC ANTIGEN  ................................ ................................ ................................ .... 56 
7.3.2  SOFT TISSUE AND BONE LESIONS  ................................ ................................ ..............................  57 
[IP_ADDRESS]  SCHEDULE OF IMAGING TIME POINTS  ................................ ................................ .....................  [ADDRESS_1074012]: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page [ADDRESS_1074013]  ................................ ................................ ..................  71 
8.1.3   PREGNANCIES  ................................ ................................ ................................ ............................  71 
8.2 INDEPE NDENT DATA MONITORING COMMITTEE  ................................ ................................ ...... 72 
9 DATA REVIEW AND DATA  MANAGEMENT  ................................ ................................ ...........  73 
9.1 SITE MONITORING  ................................ ................................ ................................ .......................  73 
9.2 DATA  COLLECTION  ................................ ................................ ................................ ......................  73 
9.3 DATABASE MANAGEMENT AND QUALITY CONTROL  ................................ ................................  73 
10 STATISTICAL METHODS AND DATA ANALYSIS  ................................ ................................  75 
10.1  ANALYSIS POPULATIONS  ................................ ................................ ................................ ...........  75 
10.1.1  PATIENT DEMOGRAPHICS AND OTHE R BASELINE CHARACTERISTICS  ................................ ..... 76 
10.1.2  TREATMENTS  ................................ ................................ ................................ ............................  76 
10.2  PRIMARY EFFICACY ANALYSIS  ................................ ................................ ................................ . 76 
10.2.1  PRIMARY EFFICACY ENDPOINT  ................................ ................................ ................................  76 
10.2.2  STATISTICAL HYPOTHESIS , MODEL AND METHOD OF ANALYSIS  ................................ ............  76 
10.2.3  SUPPORTIVE ANALYSIS  ................................ ................................ ................................ ............  78 
10.3 SECONDARY OBJECTIVES  ................................ ................................ ................................ ..........  78 
10.3.1  SECONDARY EFFICACY ENDPOINTS  ................................ ................................ .........................  78 
10.3.2  SAFETY  ................................ ................................ ................................ ................................ ..... 79 
10.4  EXPLORATORY ENDPOINTS  ................................ ................................ ................................ ....... 80 
10.4.1  QUALITY OF LIFE (QOL)................................ ................................ ................................ ...........  80 
10.4.2  SECOND LINE TREATMENT  ................................ ................................ ................................ ....... 80 
10.5  PHARMACOKINETICS  ................................ ................................ ................................ .................  80 
10.6  IMMUNE RESPONSE BIOMARKERS AND GENE EXPRESSIONS  ................................ .................  80 
10.7  SAMPLE SIZE CALCULATION  ................................ ................................ ................................ .... 80 
11 ADMINISTRATIVE PROCE DURES  ................................ ................................ ...........................  82 
11.1  REGULATORY AND ETHICAL COMPLIANCE  ................................ ................................ .............  82 
11.2  INSURANCE  ................................ ................................ ................................ ................................ . 82 
11.3  RESPONSIBILITIES OF T HE INVESTIGATOR AND IRB/IEC  ................................ ......................  82 
11.4  INFORMED CONSENT  ................................ ................................ ................................ .................  82 
11.5  LE[LOCATION_006]APHERESIS PROCEDURE INFORMED CONSENT FORM  ................................ ...................  83 
11.6  AMENDMENTS TO THE PROTOCOL  ................................ ................................ ...........................  83 
11.7  DISCONTINUATION OF TH E STUDY  ................................ ................................ ...........................  83 
11.8  STUDY DRUG SUPPLY AND RE-SUPPLY , STORAGE AND TRACKING /DRUG ACCOUNTABILITY
 [ADDRESS_1074014]: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page 7 of 96 
 
12 PROTOCOL ADHERENCE  ................................ ................................ ................................ ..........  85 
13 REFERENCES (AVAILABLE UPON REQU EST)  ................................ ................................ .........  [ADDRESS_1074015] -P QUESTIONNAIRE  ................................ ................................ ................................ .........  88 
14.2  EQ-5D QUESTIONNAIRE  ................................ ................................ ................................ ............  92 
14.3  NCI  CTCAE  ................................ ................................ ................................ ...............................  95 
14.4  PROTOCOL VIOLATIONS /DEVIATIONS  ................................ ................................ .....................  [ADDRESS_1074016]: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page [ADDRESS_1074017] OF FIGURES  
Figure 1: DCVAC/PCa Phase III study design  ................................ ................................ ................................ ...... [ADDRESS_1074018] OF TABLES  
Table 1: Visit Evaluation Schedule  ................................ ................................ ................................ .......................  52 
Table 2: ECOG performance status scale  ................................ ................................ ................................ ..............  [ADDRESS_1074019]: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page 9 of 96 
 
ABBREVIATIONS  
Abbreviation or Term*  Definition/Explanation  
ACE  angiotensin converting enzyme  
ACI active cellular immunotherapy  
ADR  adverse drug reaction  
ADT  androgen deprivation therapy  
AE adverse event  
AESI  Adverse Events of Special Interest  
ALP  alkaline phosphatase  
ALT  alanine aminotransferase  
ANA  antinuclear antibodies  
ANCA  anti-neutrophil -cytoplasmic antibodies  
aPTT  activated partial thromboplastin time  
ARS  all randomized subjects  
AST  aspartate aminotransferase  
ATC  Anatomic Therapeutic Class  
ATMP  advanced -therapi[INVESTIGATOR_781288]2+ Calcium ion  
CBC complete blood count  
CHMP  Committee for Medicinal Products for Human Use  
CMV  cytomegalovirus  
Cl- chloride ion  
CRF  case report form  
CRO  Contract Research Organization  
CRP  C-reactive protein  
CRPC  castration -resistant prostate cancer  
CT computed tomography  
DC dendritic cell  
DCVAC/PCa  Autologous active cellular immunotherapy consisting of 
dendritic cell s for prostate cancer  treatment  
DMSO  Dimethyl sulfoxide  
DNA  Deoxyribonucleic acid  
DQF  Data Query Form  
DSUR  Development Safety Update Report  
 CONFIDENTIAL  Protocol No. SP005  
  EudraCT: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page 10 of 96 
 
EBV  Epstein -Barr Virus  
EC/IEC  Ethics Committee  / Independent Ethics Committee  
ECG  Electrocardiogram  
ECOG  Eastern Cooperative Oncology Group  
eCRF  electronic case report form  
EC European Commission / European Community  
EDC  Electronic Data Capture  
EMA/EMEA  European Medicines Agency  
EOT  End of Treatment  
EOS  End of Study  
EORTC  European Organization for the Research and Treatment 
of Cancer  
EQ-5D Euro Quality of Life [ADDRESS_1074020] -P Functional Assessment of Cancer Therapy - Prostate  
FDA  Food and Drug Administration  
GCP  Good Clinical Practice  
GLP  Good Laboratory Practices  
GM-CSF granulocyte macrophage colony stimulating factor  
GMP  Good Manufacturing Practice  
GMT  gamma -glutamyltransferase  
GnRH/LHRH  gonadotropin releasing hormone/ luteinizing hormone -
releasing hormone  
HBc Ab  Hepatitis B Core Antibody  
HBs Ag  Hepatitis B Surface Antigen  
HBV  Hepatitis B virus  
HCV  Hepatitis C virus  
HHP  high hydrostatic pressure  
HIV human immunodeficiency virus  
HLA  human leukocyte antigen  
HPF high-power field 
HR heart rate  
HTLV  
IB human T -lymphotropic virus  
Investigator Brochure  
ICF Informed Consent Form  
iDCs  immature dendritic cells  
IDMC  Independent Data Monitoring Committee  
 CONFIDENTIAL  Protocol No. SP005  
  EudraCT: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page [ADDRESS_1074021]  
IRF Independent Review Facility  
ITT Intent to treat  
IVRS/IWRS  Interactive Voice Response System / Interactive Web 
Response System  
K Potassium  
Kg Kilogram  
LDH  lactate dehydrogenase  
LNCaP  androgen -sensitive prostate cancer cell line derived from 
lymph node metastasis  
LOCF  last observation carried forward  
LVEF  Left Ventricular Ejection Fraction  
NK cells  Natural killer cells  
mCRPC  Metastatic Castration Resistant Prostate Cancer  
mDCs  mature dendritic cells  
MDSC  myeloid derived suppressor cells  
MedDRA  Medical Dictionary for Drug Regulatory Activities  
Mg Magnesium  
MHC  major histocompatibility complex  
MR median reference  
MRI  magnetic resonance imaging  
MS Median survival  
MT median test  
MUGA  multiple gated acquisition  
Na Sodium  
NaCl  sodium chloride  
NCCN/EAU  National Comprehensive Cancer Network /European 
Association of Urology  
 CONFIDENTIAL  Protocol No. SP005  
  EudraCT: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page 12 of 96 
 
NCI CTCAE  National Cancer Institute - Common Terminology 
Criteria for Adverse Events  
NP nurse practitioner  
OS overall survival  
PA physician Assistant  
PBMC  peripheral blood mononuclear cells  
PCa prostate cancer  
PCR  polymerase chain reaction  
PCWG  Prostate Cancer Working Group  
PE physical examination  
PD progressive disease  
rPFS  radiographic progression free survival  
pH negative logarithm of hydrogen ion concentration 
(“power of hydrogen”)  
PP per protocol set of subjects  
PR partial response  
PSA prostate -specific antigen  
PSADT  prostate -specific antigen doubling time  
PT prothrombin time  
QoL quality of life  
RBC  red blood cell  
RECIST  response evaluation criteria in solid tumors  
RF rheumatoid factors  
RNA  ribonucleic acid  
RPE radical prostatectomy  
SAE  serious adverse event  
SAP  Statistical Analysis Plan  
SAR  serious adverse reaction  
SD stable disease  
SIV site initiation visit  
SmPC  Summary of Product Characteristics  
SOC  Standard of Care  
SPECT  single -photon emission computed tomography  
SRE skeletal related events  
S[LOCATION_006]L  State Institute for Drug Control (e.g. Czech Competent 
Authority in the Czech Republic)  
S[LOCATION_003]R  Suspected Unexpected Serious Adverse Reaction  
 CONFIDENTIAL  Protocol No. SP005  
  EudraCT: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page [ADDRESS_1074022]: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page [ADDRESS_1074023] UDY PROTOCOL SYNOPSI S  
Name [CONTACT_790]  / 
Company  SOTIO a.s.  
Investigational drug   DCVAC/PCa, active cellular immunotherapy containing autologous dendritic cells 
(DC) activated by [CONTACT_781323]-vivo 
Protocol no.  SP005  
Study phase  Phase III  
Study title  A Randomized, Double  Blind, Multicenter, Parallel -Group, Phase  III Study to Evaluate 
Efficacy and Safety of DCVAC/PCa Versus Placebo in Men with Metastatic Castration 
Resistant Prostate Cancer Eligible for 1st Line Chemotherapy  
Background  DCVAC/PCa is an active autologous cellular immunotherapy consisting of dendritic 
cells (DCs) produced ex-vivo from a patient’s monocytes which are pulsed with tumor  
cells killed by [CONTACT_781324] (HHP) and subsequently activated by a 
maturation agent.  When the activated autologous DCs are injected back into the patient 
with mCRPC an immune response is established against the cancer which may inhibit 
progre ssion and improve overall survival (OS).  
Purpose/rationale  Addition of DCVAC/PCa to Standard of Care (SOC)  Chemotherapy (docetaxel plus 
prednisone ) will result in a prolongation in OS in mCRPC subjects . 
Objectives  Primary : 
The primary objective is to show superiority of treatment with DCVAC/PCa in addition 
to SOC  (docetaxel plus prednisone ) over placebo in addition to SOC  (docetaxel plus 
prednisone ) in men with mCRPC as measured by [CONTACT_70112].  
 
Key Secondary : 
The key secondary objectives include assessments of safety, treatment group 
comparison with regards to radiographic progression free survival, time to prostate -
specific antigen progression, time to first  occurrence of skeletal related events (SRE) . 
 
Other Seconda ry: 
Show clinical benefit of treatment with DCVAC/PCa  in addition to SOC over placebo 
in addition to SOC with regard to time to radiographic progression or to skeletal related 
events  and proportion of patients with  SRE. 
 
Exploratory Objective:  
Treatment group comparison for the following measures:  Proportion of subjects 
requiring second line treatment introduction and time to second line therapy, changes 
in quality of life (QoL) and exploratory studies for search of potential biomarkers  
Endpoints  Primary efficacy endpoint:   
 Overall Survival  (OS) 
 
Key Secondary  efficacy endpoints:  
 Radiological progression free survival (rPFS) , composite of  
o radiographic progression of bone lesions  
o radiographic progression of soft tissue lesions  
o death due to any cause  
 Time to prostate -specific antigen (PSA) progression  
 Time to first  skeletal related events (SRE)  
 
 
 CONFIDENTIAL  Protocol No. SP005  
  EudraCT: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page 15 of 96 
 
Other Secondary  efficacy endpoints:  
 Time to radiographic progression or SRE  
 Proportion of patients with  SRE 
 
Safety endpoints:  
Adverse events, including laboratory abnormalities , change in vital signs and change 
in ECOG performance status.  
 
Exploratory  endpoints:  
 Evaluation of QoL using the standardized questionnaires FACT -P and EQ -5D 
(EQ-5D only in Europe ) 
 Proportion of subjects  requiring second line treatment introduction  
and time to second line therapy  
 Exploratory studies for search of potential biomarkers  
Study design  This is a randomized, double blind, placebo controlled, multicenter,  international , 
parallel -group Phase III  study to evaluate the efficacy and safety of DCVAC/PCa 
versus placebo in men with metastatic castration resistant prostate cancer (mCRPC) 
eligible for 1st line chemotherapy  with docetaxel  plus prednisone . The sample size was 
established as [ADDRESS_1074024] of:  
 Screening Period (up to 28 days).  
 Randomization – Interactive Voice/Web Response System (IVRS/IWRS) central 
randomization – 2:[ADDRESS_1074025] of Care Chemot herapy  (docetaxel 
plus prednisone ) + DCVAC/PCa or Standard of Care chemotherapy (docetaxel 
plus prednisone ) + placebo.  
 Leukapheresis Period  – all subjects will undergo a leukapheresis evaluation prior 
the leukapheresis procedure. The leukapheresis procedure itself will be performed 
within 14 days of randomization.  
 Concurrent  Treatment Period – First line Standard of Care chemotherapy  with 
docetaxel plus prednisone  will begin [ADDRESS_1074026] of Care chemotherapy  (docetaxel  plus prednisone ). DCVAC/PCa or 
placebo will be administered concurrently every 3 weeks . DCVAC/PCa or 
placebo will be administered at least [ADDRESS_1074027] chemotherapy (Day 8 -15 of chemotherapy cycle)  starting after second 
cycle of Standard of Care chemotherapy (docetaxel+ prednisone ). 
 Maintenance Boosting Period – should  first line Standard of Care chemotherapy  
(docetaxel  plus predni sone) be completed or withdrawn for any reason , the patient 
will continue on DCVAC/PCa or placebo  every 4 weeks  until the completion of 
a total of 15 doses , refusal,  intolerance or introduction of the 2nd line of antitumor 
therapy . After completion or withdrawal of DCVAC/PCa or placebo an End of 
Treatment Visit  (EOT) will be performed . 
 Follow -up Period – All subjects  will be followed until refusal, death or study 
closure . Final Analysis will be performed  upon reaching the targeted number o f 
events for analysis ( 657 deaths). Upon completion  of the follow -up period patients 
will have the  End of Study visit  performed .  
Population  Men with mCRPC who are eligible to receive first line Standard of Care chemotherapy  
with docetaxel plus prednisone  
Inclusion/exclusion 
criteria  Inclusion  
 Male 18 years and older.  
 Histologically or cytologically confirmed prostate adenocarcinoma.  
 CONFIDENTIAL  Protocol No. SP005  
  EudraCT: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page 16 of 96 
 
 Presence of skeletal and/or soft -tissue/visceral/nodal metastases according to one 
of the following criteria:  
 Confirmed pathological fracture related to the disease.  
OR 
 Confirmation of distant bone and/or soft -tissue and/or visceral metastases 
through at least one imaging modality including CT or MRI or scintigraphy 
scan (confirmation by [CONTACT_781325] (IRF) re quired)  
OR 
 Positive pathology report of metastatic lesion.  
 Disease progression despi[INVESTIGATOR_119425] (ADT) as indicated by:  
 PSA increase that is ≥ 25% and ≥ 2 ng/mL above the minimum PSA as 
reached during ADT or above the pre -treatment level, if no response was 
observed and which is confirmed by a second value 1 or more weeks later.  
OR 
 Progression of measurable lymph nodes (short axis ≥ 15 mm) or visceral 
lesion measurable per RECIST v1.1 criteria (confirmation by [CONTACT_781326]);  
OR 
 Two or more new lesions appearing on bone scan/imaging compared with 
a previous scan (confirmation by [CONTACT_781327])  
 Maintenance of castrate condition: S ubjects, who have not had a surgical 
orchiectomy, must continue with hormone therapy (GnRH/LHRH agonists or 
antagonists) to reach levels of serum testosterone of ≤ 1.7 nmol/L (50 ng/dL). The 
duration of the castration period must be at least 4 months befor e screening.   
 Laboratory criteria:  
 White blood cells greater than 4,000/mm3 (4.0 x109/L). 
 Neutrophil count greater than 1,500/mm3 (1.5 x109/L). 
 Hemoglobin of at least 10 g/dL (100g/L).  
 Platelet count of at least 100,000/mm3 (100 x109/L). 
 Total bilirubin within normal limits (benign hereditary 
hyperbilirubinaemias, e.g. Gilbert´s syndrome are permitted).  
 Serum alanine aminotransferase, aspartate aminotransferase, and creatinine 
<1.[ADDRESS_1074028].  
 Life expectancy of at least 6 months based on Investigator´s judgment.  
 Eastern Cooperative Oncology Group (ECOG) performance status 0 -2.  
 At least 4 weeks after surgery or radiotherapy before randomization.  
 A minimum of 28 days beyond initiation of bisphosphonate or denosumab therapy 
before randomization.  
 Recovery from primary local surgical treatment, radiotherapy or orchiectomy 
before randomization.  
 Signed informed consent including patient’s ability to comprehend its contents.  
 
Exclusion  
 Confirmed brain and/or leptomeningeal metastases  (other visceral metastases are 
acceptable).  
 Current symptomatic spi[INVESTIGATOR_781289].  
 Prior chemotherapy for prostate cancer  
 Patient co -morbidities:  
 Subjects who are not indicated for chemotherapy treatment with firs t line 
Standard of Care chemotherapy (docetaxel and prednisone).  
 HIV positive, HTLV positive.  
 Active hepatitis B (HBV), active hepatitis C (HCV), active syphilis.  
 CONFIDENTIAL  Protocol No. SP005  
  EudraCT: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page 17 of 96 
 
 Evidence of active bacterial, viral or fungal infection requiring systemic 
treatment.  
 Clinic ally significant cardiovascular disease including:  
 symptomatic congestive heart failure.  
 unstable angina pectoris.  
 serious cardiac arrhythmia requiring medication.  
 uncontrolled hypertension.  
 myocardial infarction or ventricular arrhythmia or stroke within a 6 
months before screening, known left ventricular ejection fraction 
(LVEF) < 40% or serious cardiac conduction system disorders, if a 
pacemaker is not present.  
 Pleural and pericardial effu sion of any CTCAE grade.  
 Peripheral neuropathy having a CTCAE ≥ grade 2.  
 History of active malignant disease (with the exception of non -melanoma 
skin tumors) in the preceding five years.  
 Active autoimmune disease requiring treatment.  
 History of severe form s of primary immune deficiencies.  
 History or anaphylaxis or other serious reaction following vaccination.  
 Known hypersensitivity to any constituent in of the DCVAC/PCa or 
placebo product  
 Uncontrolled co -morbidities including, psychiatric or social conditio ns 
which, in the Investigator’s opi[INVESTIGATOR_1649], would prevent participation in the trial.  
 Systemic corticosteroids at doses greater than 40 mg hydrocortisone daily or 
equivalent for any reason other than treatment of prostate cancer (PCa) within 6 
months before r andomization.  
 Ongoing systemic immunosuppressive therapy for any reason.  
 Treatment with anti -androgens, inhibitors of adrenal -produced androgens or other 
hormonal tumor -focused treatment performed on the day of randomization  (except 
for GnRH/LHRH agonists  or antagonists), to exclude possible anti -androgen 
withdrawal response. This criterion is not applicable to subjects who have never 
responded to anti -androgen treatment, as there is no risk of anti -androgen 
withdrawal response.  
 Treatment with immunotherap y against PCa within 6 months before randomization.  
 Treatment with radiopharmaceutical within 8 weeks before randomization.  
 Participation in a clinical trial using experimental therapy within 4 weeks before 
randomization.  
 Participation in a clinical trial using immunological experimental therapy (e.g., 
monoclonal antibodies, cytokines or active cellular immunotherapi[INVESTIGATOR_014]) within  6 
months before randomization.  
 Refusal to sign the informed consent.  
Patient numbering  Subjects  will be centrally randomized and assigned a unique study number using an 
IVRS/IWRS system.  
Investigational and 
Standard of Care drugs  Investigational therapy:   
DCVAC/PCa is an active autologous cellular immunotherapy produced under GMP -
conditions. DCVAC/ PCa is prepared on an individual basis from the peripheral blood 
mononuclear cells (PBMC) of the patient obtained by [CONTACT_74886].  DCs are generated 
from the harvested PBMCs using IL -4 and GM -CSF. Subsequently, the immature DCs 
(iDCs) are exposed to kille d tumor  cells (LNCaP) at a DC: tumor  cell ratio of 5:1.  
Tumor  cell-pulsed DCs are then matured by [CONTACT_422302] -3 ligand. Cells are then 
cryopreserved and stored in liquid nitrogen. On the day of drug injection, a suspension 
of 1×107 LNCaP -pulsed mature DCs is unfrozen, re -suspended in 0.9% saline to a total 
volume of 5 ml and then injected subcutaneously in the inguinal and axillary lymph 
node area  in two 2.5 m L volumes . The placebo used for the study will be identical to 
the study d rug without the active drug substance (DCVAC/PCa).  
 CONFIDENTIAL  Protocol No. SP005  
  EudraCT: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page [ADDRESS_1074029] of Care therapi[INVESTIGATOR_014]:  Investigators should use Standard of Care therap y 
(docetaxel  plus prednisone ) with authorization for their country and should reference 
the prescribing informat ion provided with the product when treating the subjects . 
Dose, regimen, 
treatment cycle  Subjects  receiving DCVAC/PCa or placebo will all receive prepared study medication 
according to the treatment plan. Concurrently with Standard of Care ( docetaxel  plus 
prednisone ) DCVAC/PCa or placebo will be given in 3 weeks intervals  (with an 
acceptable window of ± 7 days).  DCVAC/PCa or placebo will be administered at least 
[ADDRESS_1074030] chemotherapy ( Day 8 -15 of 
chemother apy cycle ). 
After discontinuation of Standard of Care chemotherapy for any reason , each following 
dose of DCVAC/PCa or placebo will be given in 4 weeks intervals (with an acceptable 
window of -7/+14 days) for up to a total of [ADDRESS_1074031] of Care chemotherapy (docetaxel plus 
prednisone ) until completion, refusal, intolerance, disease progression or death and 
may be treated with subsequent therapi[INVESTIGATOR_713737]’s discretion (see section  
6.1.2 ) until completion, refusal, death or study closure. When 2nd line therapy is 
introduced to patient , DCVAC/PCa will be discontinue d.  
Supply,  preparation, 
and administration  DCVAC/PCa is an autologous cellular suspension, 15 doses are manufactured  from  an 
autologous sample, 1 mL i.e. 1×107 pulsed mature DCs per dose, every dose diluted 
with 0.9% saline to a final volume of 5 mL. Each dose is given in 2 separate 2.5 mL 
subcutaneous injections , one injection to  an inguinal lymph node area and one to an  
axillary lymph node area.  Treatments are rotated to alternate areas.  
Visit schedule and 
assessments   Laboratory evaluations during the Concurrent Treatment Period, while patient is 
on first line chemotherapy:  
 Hematology  every 3 weeks.  
 Blood biochemistry every 3 weeks (includes ALP and LDH).  
 TSH every 12 weeks  
 PSA every 12 weeks  (coordinated with imaging assessments) . 
 Urinalysis every 6 weeks.  
 Laboratory evaluations during the Maintenance Boosting Period, after termination 
of first line chemotherapy:  
 Hematology  every 4 weeks  until End of Treatment Visit . 
 Blood biochemistry every  4 weeks (includes ALP and LDH)  until End of 
Treatment Visit . 
 TSH every 12 weeks  until End of Treatment Visit.  
 PSA every 12 weeks  (coordinated with imaging assessments)  until confirmed 
progression  or introduction of 2nd line therapy . 
 Urinalysis every 12 weeks  until visit End of Treatment visit   
 Blood sampling for research purposes – at Randomization , prior to the 5th dose of 
DCVAC/PCa or placebo, at  the End of Treatment  visit. 
 Serum testosterone level at screening if historical ly measured value  (older th an 4 
months before screening) doesn´t exist.  
 Complete Physical exam at screening.  
 Symptom Directed Physical exam, vital signs every visit post screening.  
 Imaging will be conducted every 12 weeks (± 7 days) (skeletal scintigraphy/CT  
(MRI) ) until confirmed progression  or until introduction of 2nd line therapy . 
 CONFIDENTIAL  Protocol No. SP005  
  EudraCT: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page 19 of 96 
 
Special safety 
assessment(s)  Safety assessments consist of monitoring and recording of all AEs, including serious 
adverse events (SAEs), the regular monitoring of hematology , blood biochemistry and 
urine values, clinical evaluation  of vital signs, physical examinations , performance 
status  using ECOG scale, and radiological examinations .  
An independent Data Monitoring Committee ( IDMC) will be constituted to regularly 
evaluate  blinded safety data.  
Patient reported 
outcomes  QoL based on the questionnaires FACT -P and EQ -5D (EQ -5D only in Europe ). 
Biomarkers  PSA measured as part of  secondary endpoint of disease progression.  
Exploratory Biomarker 
Immunogenicity 
studies  Blood samples for research purposes will be obtained from all subjects  at 
Randomization , at cycle  [ADDRESS_1074032] of five members, including  one statistician.  The 
frequency of IDMC meetings will be spelled out in the IDMC charter.  
Statistical methods and 
data analysis  It is planned that the data from all centers that participate in this protocol will be used, 
so that an adequate number of subjects  will be available for analysis (ITT population).  
 
Data will be summarized with respect to demographic and baseline characteristics, 
efficacy observations and measurements, and safety observations and measurements.  
 
The assessment of efficacy will be based on a sample size of approximately 1170 
subjects  (i.e., events of 657 deaths).  The study will have 80% power to dete ct a hazard 
ratio of  0.792 for death in the group receiving DCVA/PCa plus Standard of Care 
chemotherapy  (docetaxel plus prednisone ) as compared with the group receiving 
placebo plus Standard of Care Chemotherapy  (docetaxel plus prednisone ). This sample 
size was calculated by [CONTACT_7702] a median survival of 24 months for the DCVAC/PCa 
group and 19 months for the control group, with a two -sided significance level (alpha) 
of 0.05, allocation ratio 2:1 of DCVA/PCa versus placebo arm, an enrollment period 
of appro ximately [ADDRESS_1074033] of the overall survival (OS) 
endpoint to compare subjects receiving  DCVAC/PCa in addition to Standard of Care  
(docetaxel plus prednisone ) (Arm A) versus those receiving placeb o in addition to 
Standard of Care  (docetaxel plus prednisone ) (Arm B) for the Intent -to-Treat (ITT) 
population . Patients will be randomized in a 2:1 ratio, stratified by [CONTACT_11338] (US vs 
Other), prior therapy  (abiraterone or enzalutamide or neither of the two ) and, ECOG 
Score (0,  1 vs 2).  The overall type I error rate will be controlled at 0.05.  At the final 
analysis, a final p -value of ≤ 0.0455 is required to be considered statistically significant.  
(East 5.4 software with ‘Null’ variance was used for total events and statistical 
significance boundary determination ). 
The Cox proportional hazards regression model will be used to analyze OS data. 
Estimated hazard ratio and corresponding two -sided 95% c onfidence interval will be 
calculated. Estimated median survival time and survival rate will be calculated and 
presented by [CONTACT_1570].  
 
The assessment of safety will be based mainly on the comparison of frequency of AEs 
and related AEs (ADRs) betwee n groups. Adverse events will include clinically 
significant laboratory abnormalities.  
 
Patient reported outcomes will be assessed using the questionnaire s FACT -P and EQ -
5D (EQ-5D only in Europe) . 
 CONFIDENTIAL  Protocol No. SP005  
  EudraCT: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page 20 of 96 
 
Number of subjects , 
centers and location, 
predicted duration  Total number of subjects : 
Number of sites:  
Number of subjects  per site:  
Location of sites:  
Predicted duration:  1170 subjects  
280 – 320 centers  
 4 – [ADDRESS_1074034]: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page 21 of 96 
 
1 BACKGROUND  
 
1.1 Overview of Prostate Cancer  
Prostate cancer (PCa) is the second most common form  of cancer and the sixth leading cause 
of cancer death among men worldwide with an estimated 899,[ADDRESS_1074035] incidence in 2008 was estimated to be in [LOCATION_009] (Martinique 173.3/100,000) 
and in Northern Europe  (Ireland 126.3/100,000, Norway 115.6/100,000, and Sweden 
114.2/100,000). In Australia and New Zealand the estimated incidence in 2008 was 
104.2/100,000. In Central and Eastern Europe the average incidence of prostate cancer in 2008 
was estimated to be 28. 5/100,000 (57,554 cases), in Northern Europe 75.2/100,000 (67,638 
cases), in Southern Europe 50.2/100,000 (79,923 cases) and in Western Europe 94.1/100,000 
(170,007 cases).  In the [LOCATION_003], prostate cancer accounted  for an estimated 186,220 new cases in 
2008 (i ncidence 83.8/100,000 men).2 It is estimated that 240,890 men were diagnosed with the 
disease and 33,730 died of it in the [LOCATION_003] in 2011.3 An estimated 238,590 new cases of prostate 
cancer will occur in the US during 2013  with an estimated 29,720 deaths in 2013, prostate 
cancer is the second -leading cause of cancer death in men in the US.4 
 
Well-established risk factors for PCa are older age, black race/ethnicity, and a family history of 
the disease.[ADDRESS_1074036] a risk of diagnosis that is 1.6 times above the risk in white  
men and risk of death that is 2.5 times greater.6 
 
Prostate cancer treatment options include surgery (prostatectomy), radiotherapy, hormonal 
manipulation and chemotherapy.7,8 Prostate cancer can be cured at the stage of localized organ -
confined disease, in which 10 -year survival is between 75 and 93%.9 In spi[INVESTIGATOR_781290] (RPE) or primary curative radiotherapy, relapses occur in approximately 
30% of subjects  within [ADDRESS_1074037] significantly poorer prognosis.  
Treatment of locally advanced disease consists of a combination of surgery or radiotherapy and 
androgen deprivation therapy (ADT).  Subjects  with metastatic disease are candidates for ADT 
by [CONTACT_781328]. ADT leads to apoptosis of primary tumor cells as 
well as metastases. ADT reduces symptoms and delays the time to progression (TTP), however, 
it does not prolong the O S.  
 
Average responsiveness to castration for men with metastases varies between 18 and 48 months. 
Frequently, despi[INVESTIGATOR_532144], disease progression occurs, due to the emergence of resistant tumor 
cells and castration -resistant  disease develops.  Median survival  of metastatic castration -
resistant  subjects  varies between 12–[ADDRESS_1074038]: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page [ADDRESS_1074039] now been approved by [CONTACT_2165] (FDA) agency, for the 
treatment of castrat ion resistant prostate cancer (CRPC) including chemotherapy (docetaxel and 
cabazitaxel), secondar y hormonal  manipulation (abiraterone , enzalutamide ), 
radiopharmaceutical Radium -223 dichloride  to treat bone metastas es and cell -based 
immunotherapy (sipuleucel -T). Each of these prolongs median survival by a few months. As a 
result, there is a clear unmet medical need for an agent that can provide clinically relevant 
improvement in the OS or/and progression free survival (PFS) without adding to the existing 
burden of  intolerability. DCVAC/PCa is being considered  as an additional option for the 
mCRPC subjects  requiring Standard of Care 1st line chemotherapy, to prolong OS.  
 
1.[ADDRESS_1074040] cell-based 
immunotherapy  (sipuleucel -T; April 29, 2010; BL 125197/0; License No. 1749 ) as the first 
application of this new approach in clinical practice.  
 
Immunotherapy is based on the induction of tumor  cell specific immune response that 
subsequently recognizes and destroys tumor  cells.  Cell-based i mmunot herap y must stimulate 
specific immune responses against cancer cells, and the immune responses must be sufficient 
to overcome the immuno -suppressive mechanisms of tumor  tissue micro -environment.[ADDRESS_1074041] shown that chemotherapy can be combined with a cell-based 
immunotherapy for prostate -cancer without blunting the immune response to the 
immunotherapy .13 A summar y of immunotherapy of prostate cancer is provided in the 
Investigator ’s Brochure (IB).  
 
The approach tested in this study represents a patient specific active cellular immunotherapy 
(ACI) using autologous dendritic cells differentiated from peripheral blood monocytes and 
presenting tumor  antigens derived from prostate cancer cell line killed by [CONTACT_781329]. In the present study, ACI will be combined with the first line chemotherapy ( docetaxel  
plus prednisone ) in accordance with the concept of “chemo -immunotherapy”.  
 
1.3 Overview of DCVAC/PCa  
DCVAC/PCa is an autologous active cellular immunotherapy which was previously considered 
to be a medical treatment, not requiring drug -status authorization. In 2007 the European Union 
(EU) legislation classified this cellular therapy as a drug belonging to the category of advanced -
therapie s medicinal products (ATMP) according to EC  1394/2007 . In the [LOCATION_003], Human Cells, 
Tissues, and Cellular and Tissue Based Products are under regulation 21 CFR part 1271 issued 
in 2001.  From October 2011 active cellular immunotherapy for cancer treatment is guided by 
[CONTACT_781330]: Clinical Considerations for Therapeutic Cancer  Vaccines . 
 CONFIDENTIAL  Protocol No. SP005  
  EudraCT: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page 23 of 96 
 
In compliance with these regulations and guidelines, DCVAC/PCa is produced under Good 
Manufac turing Procedure (GMP) conditions.  DCVAC/PCa is prepared individually from the 
patient’s autologous peripheral blood mononuclear cells (PBMCs) obtained by [CONTACT_74886]. 
Immature DCs (iDCs) are differentiated from peripheral blood monocytes in the presence  of 
IL-4 and GM -CSF.  Subsequently the iDCs are exposed to a human prostate adenocarcinoma 
cell line (LNCaP) killed by [CONTACT_781331] a DC: tumor cell ratio of 5:1. LNCaP -
pulsed DCs are then matured by [CONTACT_422302] -3 ligand (Poly I:C), incubated for 12  to 20 hours at 
37oC/5% CO 2. Cells are then cryopreserved in CryoStor CS10 freeze medium at a concentration 
of 1x107/mL and stored in liquid nitrogen.  These cells are stable for at least 18 months and 
aliquots can be stored at a drug depot and distributed to the clinical sites.  On the day of drug 
administration, an aliquot of 1×107 LNCaP -pulsed mature DCs is thawed, re -suspended in 0.9% 
saline to a volume of 5  mL, and divided into two 2.5  mL injections for the patient’s comfort. 
The dose is then injected subcutaneously in the inguinal or and axillary region s within [ADDRESS_1074042] been conducted to characterize the pote ncy of DCVAC/PCa and 
to determine the biological activity of this cell -based immunotherapy.  The guidelines on human 
cell-based medicinal products (EMEA/CHMP/410869/2006) state that in-vitro  studies may 
replace animal studies if relevant animal models have not been developed.  As animal models 
are not relevant for this kind of product due to its autologous nature, the pharmacokinetic 
properties and safety of the product were evaluated in human pi[INVESTIGATOR_7602].  
 
The capacity to activate antigen specific cytotoxi c lymphocytes is a hallmark of mature DCs.  
The capacity of mature DCs to induce antigen specific T cells is tested in the potency assay.  In 
this test, mature DCs are pulsed with the mixture of HLA class I binding peptides from influenza 
virus, CMV and EBV and tested for their capacity to expand virus specific T cells.  As 
documented in internal validation study “Potential of mature dendritic cells as with regards to 
activation of specific cytotoxic T -lymphocytes ” (VAL -54), mature DCs present in the 
DCVAC/PCa  efficiently expand virus specific T cells after one week of co -culture with 
autologous T lymphocytes.  
 
The ability to induce tumor -specific cytotoxic CD8+ T lymphocytes can also be tested using 
mature DCs pulsed with killed tumor cells.  DCs possess the c apacity to present exogenous 
antigens (such as apoptotic tumor cells) at MHC class I molecules and thus can activate both 
CD4 and CD8 tumor cells specific T lymphocytes.  DCVAC/PCa activates both CD4 and CD8 
LNCaP specific T lymphocytes after two weeks of c ulture.14 
 
1.3.2 Clinical development  
 
Phase I/II  
The first -in-human study with DCVAC/PCa was initiated in 2008 (after GMP approval of 
manufacturing process by [CONTACT_781332]: S[LOCATION_006]L - certificate for 
manufacturer No [ZIP_CODE]/2/INS/07) in University Hospi[INVESTIGATOR_781291], Prague, Czech Republic.  After 
local ethical committee approval, DCVAC/PCa was administered to the initial first patient, a 
 CONFIDENTIAL  Protocol No. SP005  
  EudraCT: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page 24 of 96 
 
69 year old man with CRPC who failed docetaxel treatment.15 An additional nine CRPC 
subjects  (60-83 years, median 69 years) have been  treated with DCVAC/PCa after the first line 
chemotherapy failure, concomitantly with the first line chemotherapy or cell-based 
immunotherapy alone if chemotherapy was contraindicated.  The median survival of these 
subjects  with very advanced CRPC was longer than the survival estimated by [CONTACT_781333]16 (for details, see IB). Up to 25 doses  of DCVAC/PCa were administered  in 5-7 
weeks interv als and no serious adverse reactions (SARs) have been reported.  
 
The investigator -driven academic study registered as EudraCT 2009 -017295 -24 was initiated 
in July 2010. In this on -going study, 17 subjects  - median age 68 years (58 -78 years), have been 
treated by [CONTACT_781334] -immunotherapy. DCVAC/PCa is administered  in combination with 
docetaxel at the  standard dose of 75 mg/m2 every 3 weeks and prednisone  5 mg twice daily.  
The primary endpoint of this study was safety, secondary endpoint was OS and the presence of 
tumor  specific immune response.   
 
As part of this study, a bio-distribution  study was performed using DCVAC/PCa labeled with 
indium (111In)-oxine.  Labeled DCVAC/PCa in the final volume of 1  mL (6 MBq/ mL) was 
administered subcutaneously into the bilateral axillary and inguinal areas.  Nuclear scintigraphy 
and SPECT fused with low -dose CT images were used to visualize the migration of 
DCVAC/PCa to the lymph nodes.  The effectiveness of labeling was 81% . Scintigraphic images 
of these areas were carried out for at 1, 4, 24, and [ADDRESS_1074043]/low -dose CT scans were performed targeting the application site.  Imaging methods 
showed that after DCVAC  administration, labeled DCs migrated into the regional lymph nodes 
(see IB).  
 
In 2010, another investigator -driven academic phase I/II single -center open -label study was 
initiated in prostate cancer subjects  with rising PSA within 2 years after primary prostatectomy 
or at any tim e after salvage radiotherapy ( EudraCT: 2009 -017259 -91). The primary end -point 
is safety and toxicity, secondary end -points are PSA response and immunological response.  
 
The number of subjects  enrolled in this study was extended from 15 to 25 by a protocol  
amendment in 2011. In this study, DCVAC/PCa is administered every 4 weeks as a 
monotherapy for the period of one year.  Metronomic cyclophosphamide 50  mg daily for one 
week is administered prior to the initiation of the active cancer immunotherapy. In a pr otocol 
amendment, extension of the administration period has been approved in those subjects  who 
experienced prolongation of the PSADT on immunotherapy in comparison with the pre -
treatment period.  This study is still ongoing , 24 subjects  were enrolled in the study.  Median age 
of this group of  enrolled  subjects  is 63  years (51 -74 years). Preliminary data show the 
prolongation of PSADT in the majority of subjects  during immunotherapy in comparison with 
the pre -treatment period (see IB).  
 
Safety  
All subjects  are followed for possible induction of auto -immunity at one month intervals.  
Evaluated parameters include: serum antibody concentrations (IgG, IgA, IgM, IgE), 
 CONFIDENTIAL  Protocol No. SP005  
  EudraCT: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page 25 of 96 
 
complement C3 and C4 concentrations, detection of monoclonal M component, an tinuclear 
antibodies (ANA), anti -neutrophil – cytoplasmic antibodies (ANCA), anti -Fc Ig antibodies 
(rheumatoid factors in IgG, A and M isotypes – RF IgG, RF IgA and RF IgM), anti -
transglutaminase antibodies, CRP. So far, there have been no significant labo ratory changes in 
screened parameters before, during or after the study treatment. One patient had detectable RF 
IgM without clinical signs of rheumatic disease before immunotherapy and the level did not 
fluctuate during the treatment period.   
 
As of March 2013, [ADDRESS_1074044] been administered to the 50 subjects  in the 
phase I/II studies ; 40 subjects  in the framework of the two clinical trials (EudraCT 2009 -
017259 -91 and 2009 -017295 -24) and 10 subjects  on an individual basis outside the s cope of 
the clinical trials starting in 2008.  
 
Out of 45 reported SAEs within the phase I/II clinical studies with DCVAC/PCa including 
subjects  treated on individual basis (cumulative number from DSUR #1 and DSUR #2), none 
were  assessed as a DCVAC/PCa -related SAE and the majority of them were associated with 
the progression of underlying disease. During the current reporting period, the ongoing clinical 
program with DCVAC/PCa has not raise any new safety concerns associated with the 
investigated immunothera py. The most common ly reported AEs encompassed fatigue, 
gastrointestinal conditions, infections including renal and urinary disorders, and 
musculoskeletal pain. Autoimmunity examinations performed has not indicate d any higher risk 
of autoimmunity in the subjects  receiving DCVAC/PCa.  No suspected unexpected serious 
adverse reaction (S[LOCATION_003]R) was reported by [CONTACT_76617].  No adverse events were 
recorded linked to the leukapheretic procedure.  The first dose was administered to  hospi[INVESTIGATOR_781292].  All other applications were administered in out -patient 
departments with 1 hour of observation. As no acute SAR related to study drug application 
administration has occurred so far, for future  studies, out -patient depart ment DCVAC/PCa 
administration is recommendable . 
 
Phase II  
A low production capacity in the University Hospi[INVESTIGATOR_781293] (2 -3 individual 
DCVAC/PCa per month) and limited financial academic resources did not allow for further 
extension of clinical trials to fulfill all requirements necessary for the registration of this 
individual product. The biopharmaceutical company SOTIO  a.s. assumed the responsibility for 
the further clinical development of DCVAC/PCa. The SOTIO a.s. production facility  (with 
capacity for up to 60 individual DCVAC/PCa productions monthly) was opened in spring 2011 
and received GMP status in autumn 2011.   
 
SOTIO has conducted regulatory meetings with the European Medicinal Agency (EMA) and 
Food and Drug Administration (FD A) to discuss the manufacturing and clinical development 
plan of DCVAC/PCa.  
 October 2010, EMA scientific advice for manufacturing processes 
EMEA/ CHMP/SAWP/261301/[ADDRESS_1074045]: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page 26 of 96 
 
 December 2011 SOTIO  a.s. received a certificate of GMP compliance as a manufacturer 
from Czech Regulatory Authority (S tate institute for drug control – S[LOCATION_006]L) Ref. No. 
sukls127848/2011 which fulfills EMA requirements.  
 January 2012, EMA scientific advice on preclinical and clinical development plan 
EMEA/CHMP/SAWP/ [ZIP_CODE] /2012  and EMEA/CHMP/SAW P/[ZIP_CODE] /2012.  
 March 2012, SOTIO  a.s. had a pre -IND face -to-face meeting with FDA.  
  
Based on the outcomes from the meeting with the EMA in 2010, four phase II trials were 
designed in 2011.  These were approved by [CONTACT_781335] (S[LOCATION_006]L) 
in December 2011 and initiated in March 2012:  
  
Clinical Trial SP001  (Eudra CT: 2011 -004735 -32): randomized, open -label, parallel -group, 
multi -center phase II clinical trial of active cellular immunotherapy with product DCVAC/PCa 
in patients with castrate -resistant prostate cancer.  (In combination with docetaxel)  
 
Clinical  Trial SP002  (Eudra CT: 2011 -004986 -34): randomized, open -label, parallel -group, 
multi -center phase II clinical trial of active cellular immunotherapy with product DCVAC/PCa 
in combination with hormone therapy in patients with metastatic prostate cancer.  
 
Clinical Trial SP003  (Eudra CT: 2011 -004985 -14): randomized, open -label, parallel -group, 
multi -center phase II clinical trial of active cellular immunotherapy with product DCVAC/PCa 
in patients with localized prostate cancer after primary radical prostatec tomy.  
 
Clinical Trial SP004 (Eudra CT: 2011 -004967 -65): randomized, open -label, parallel -group, 
multi -center phase II clinical trial of active cellular immunotherapy with product DCVAC/PCa 
in patients with localized high -risk prostate cancer after primary radiotherapy.   
 
As of February  2013 , there were 233  subjects  enrolled/screened in total in the four phase II 
trials, 183  of them being randomized by [CONTACT_9179] 6, 2013. 79 of these had the immune therapy 
treatment started.  
 
A DSUR covering the period 28 -December 2011 through 27 -December -2012, was submitted 
in February 2013 . There were 16 SAEs reported in 8 subjects from clinical trials during the 
reporting period covered by [CONTACT_781336]. Only t wo SAE subjects  out of those 8 were exposed to 
DCVAC/P Ca at the time of the event. None of the reported SAEs were related to the study drug 
DCVAC/PCa. No S[LOCATION_003]R has been reported in that period.  
 
Phase III  
SOTIO is trying to find the most effective way to a complete global clinical development 
process.  Based o n discussions with the FDA and the EMA, the proposed phase III clinical trial 
targets [LOCATION_003] and European subjects  with mCRPC, who are eligible for the initiation of docetaxel  
treatment. Enrolled subjects  will receive DCVAC/PCa or placebo in combination  with 
docetaxel  plus prednisone . We believe that the mCRPC population selection will serve to 
demonstrate clinical efficacy while maintaining clinical trial feasibility.  Targeting earlier stages 
of the disease might translate into better efficacy, however,  the cost and duration of the clinical 
 CONFIDENTIAL  Protocol No. SP005  
  EudraCT: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page [ADDRESS_1074046] of Care Therapi[INVESTIGATOR_781294], docetaxel 75mg/m2 and prednisone  5 
mg bid every 3 weeks was approved by [CONTACT_34033] 2004 and has become the “standard of care” 
first-line chemotherapy for CRPC.17,[ADDRESS_1074047] study of one thousand and six subjects , TAX 
327, showed an OS rate significantly higher (P=0.009) in the group treated every 3 weeks with 
docetaxel compared to treatment with mitoxantrone.  The median duration of survival was 18.9 
months in the group given docetaxel compared to 16.5 months in the mitoxant rone group 
(P=0.002). The second study compared the combination of docetaxel/estramustine to 
mitoxantrone/ prednisone  in 684 subjects . The median duration of survival was significantly 
improved with docetaxel/estramustine over mitoxantrone/ prednisone  (17.5 vs. 15.6 months, 
respectively, ( p=0.01) and superior median TTP was also detected (6.3 vs 3.2 months, 
respectively, p=0.001) in subjects  treated with docetaxel/estramustine.   
 
Four drugs were approved for the treatment of mCRPC subjects  after docetaxel failure ( post-
docetaxel   
 Cabazitaxel in combination with prednisone  is indicated for the treatment of subjects  with 
mCRPC previously treated with a docetaxel  based  regimen.  
 Abiraterone is indicated with prednisone  or prednisolone for the treatm ent of mCRPC in 
adult men whose disease has progressed on or after a docetaxel -based chemotherapy 
regimen.  
 Enzalutamide was approved for adult mCRPC subjects  with metastatic castration -resistant 
prostate cancer who have progressed on or after docetaxel th erapy. Enzalutamide doesn't 
require concomitant steroids.  
 Radium -223, an alpha particle -emitting radioactive therapeutic agent was approved for the 
treatment of subjects  with castration -resistant prostate cancer, symptomatic bone 
metastases and no known visceral metastatic disease.  
 
Abiraterone has also been recently approved in a pre-docetaxel setting.  This protocol allows for 
use of abiraterone  in the pre -docetaxel sett ing in line with the approved indication . Prior 
treatment with abiraterone (or enzalutamide) represents one of the stratification criteria at 
randomization to ensure similar proportion of abiraterone pre -treated subjects  within 
DCVAC/PCa and placebo treatment arms.  
 
1.5 History of Amendments  
 
SP005 Protocol version 
(date)  Prepared for 
submission  Key points  for creation of an updated protocol version  
 (not all changes are listed in this overview)   
v.1.1 (07M ar2013)  VHP No. 201302  
(positive decision  
19M ar2013)  For v ersion 1.[ADDRESS_1074048]: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page 28 of 96 
 
SP005 Protocol version 
(date)  Prepared for 
submission  Key points  for creation of an updated protocol version  
 (not all changes are listed in this overview)   
v.02 (10M ay2013)  IND No. 015255  
(initial submission 
28M ay2013)  Version 02 was based on v.1.1 and was modified for IND 
submission to FDA in [LOCATION_003]. (Key changes included – 
specification of 1st line chemotherapy as docetaxel and 
prednisone and update of DCV AC/PCa safety information 
based on DSUR issued in Fe bruary 2013 ; specification of 
exploratory studies on biomarkers; updated list of 
approved 2nd line c hemotherapi[INVESTIGATOR_014] ).  
v.03 (01A ug2013)  IND No. 015255 
(Follow up 
submission 
09Aug2013)  Version 03 was based on v.02 and was modified per 
feedback received from FDA. (Key changes included –
Discontinuation of DCVAC/PCa or placebo with 2nd line 
chemo therapy; Treatment period divided into [ADDRESS_1074049] line chemotherapy with 
DCVAC/PCa or placebo and Maintenance Boosting 
period post docetaxel -prednisone & prior 2nd line-
chemotherapy ; changes connected with this design 
change ; updated list of approved 2nd line chemotherapi[INVESTIGATOR_014];  
Amendment of stratification criteria, updated statistical 
section ] 
v.04 (05Dec2013 ) VHP No.201302 
Substantial 
Amendment  / IND 
No. [ADDRESS_1074050] been adjusted  to match properly the new design in 
v.03 (Study drug discontinuation, End of Treatment, 
Follow -up for survival);  secondary endpoints w ere 
modified to better fulfill PCWG2 recommendations ; 
inclusion and exclusion criteria  were modified  per 
PCWG2 guidelines ; corrected statistical section  and 
decreased number  of stratification criteria )  
v.05 (1 6Oct2014)  VHP Substantial 
Amendment No.2 /  
IND No. 015255  
Follow up 
submission  Version 05 include s updates base d on current experience 
from the clinical trial - clarified inclusion/exclusion 
criteria;  updated sections on patient follow -up for long 
term survival ; sections related to safety were updated to 
improve understanding . Sections on interim analysis and 
statistical analyses were updated based on feedback 
received from FDA. Section on exploratory studies was 
updated to include possibility of pharmacogenomics 
research.  
v.05.1 (13Jan2015)  IND No. 015255 
(Follow up 
submiss ion) 
US specific protocol  Change in the exclusion criterion. It is possible to shorten 
the washout period for ADT.  
v. 05.2 ( 03Aug 2015)  IND No. 015255 
(Follow up 
submission)  
US specific protocol  Version 05 .2 introduces : clarification  of follow -up 
procedures applicable to patients for whom leukapheresis 
or production failed, or who have not received 
DCVAC/PCa or placebo for other reasons ; clarification 
that no further  radiological examinations of a patient  will 
be required for this tri al after confirmation of radiological 
progression or introduction of 2nd line chemotherapy ; 
changes related to transfer of pharmacovigilance 
responsib ilities for safety monitoring and reporting  from 
Chiltern to SOTIO ; administrative changes in  the 
Declaration of the Investigator  
 CONFIDENTIAL  Protocol No. SP005  
  EudraCT: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page 29 of 96 
 
SP005 Protocol version 
(date)  Prepared for 
submission  Key points  for creation of an updated protocol version  
 (not all changes are listed in this overview)   
v. 06.0 (28Aug2015)  VHP Substantial 
Amendment No.04  Version 06.0 includes the same changes as US -specific 
versions 05.1 and 05.2 : change in wording of the 
exclusion criterion that shortens the ADT washout period; 
clarification of follow -up procedures applicable to 
patients for whom leukapheresis or production failed, or 
who have not received DCVAC/PCa or placebo for other 
reasons; clarification that no further radiological 
examinations of a patient will be required for  this trial 
after confirmation of radiological progression or 
introduction of 2nd line chemotherapy; changes related to 
transfer of pharmacovigilance responsibilities for safety 
monitoring and reporting from Chiltern to SOTIO; 
administrative changes in the  Declaration of the 
Investigator; Version 06.0 additionally includes the 
introduction of the EQ-5D questionnaire  (only in Europe)  
and clarification that ECOG performance status is 
measured also at Randomization.  
v. 07.0 ( 08Mar 2018)  VHP Substantial 
Amendme nt 
No.08/IND No. 
015255 (Follow up 
submission)  
  Deletion of information on third -party vendors  
 Deletion of information on interim analysis which will 
not be performed  
 Clarification that the date of randomization is Day 1 
and not Day 0  
 Update of the sections on statistics according to the 
updated SAP 
 Clarification that ECOG performance status is 
measured also at Randomization   (already in 
European v. 06.0)  
 Introduction of the EQ-5D questionnaire ( only in 
Europe ) (already in European v. 06.0)  
 Safety reporting clarifications  
  
 CONFIDENTIAL  Protocol No. SP005  
  EudraCT: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page 30 of 96 
 
2 STUDY RATIONALE/PURPOSE  
For prostate cancer subjects  with metastatic disease, androgen ablation with surgery or drugs 
remains the standard of care. The majority of subjects  initially respond, but despi[INVESTIGATOR_781295], all eventually progress and become castrat ion resistant a fter a median duration of 
approximately 18-[ADDRESS_1074051] developed symptomatic or rapi[INVESTIGATOR_781296]/castrat ion resistant metastatic PCa with a survival advantage of about [ADDRESS_1074052] to the prevailing view of chemotherapy as an immuno -suppressive regimen, there is 
now ample evi dence of chemotherapy promoting the immune response. It has been shown that 
certain forms of chemotherapy can cause immunogenic cancer cell death and thus promote 
induction of anticancer immunity.13 
 
In the proposed study population DCVAC/P Ca immunotherapy will be added to the 
chemotherapy with docetaxel  and prednisone . Docetaxel is a taxane which binds to the β -
subunit of tubulin and affects microtubule polymerization, leading to cell -cycle arrest at the 
G2/M stage and subsequent cell death.  In humans, there is circumstantial evidence that taxanes 
can stimulate the anti -cancer immune response. A cohort of subjects  with breast cancer treated 
with taxanes showed enhanced T cell and NK -cell functions compared to subjects  untreated 
with taxanes.20 
 
Furthermore, docetaxel administration considerably decreased myeloid derived suppressor cells 
(MDSC) proportion in mice models. A  recent study showed that docetaxel could reverse 
MDSC -mediated immune suppression and modulate the tumor  micro -environment, thereby 
[CONTACT_781337] -based therapi[INVESTIGATOR_014].[ADDRESS_1074053]: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page [ADDRESS_1074054] in ad dition to reducing tumor burden.24-26 Initiation  of chemotherapy 
prior to vaccination would be an option, if we want to reduce the level of suppressive cells.  
Thus, the combination of chemotherapy with immunotherapy is an attractive strategy that merits 
clinical investigation in mCRPC.  
The strategy of Sotio ’s clinical program in cancer immunotherapy is based on the assumption 
that cancer immunotherapy as a standalone treatment may be efficacious at the stage of the 
low tumo r cell burden, ideally at the stage of the minimal residual disease. At advanced stages 
of the disease, cancer immunotherapy alone has little chance to affect the established 
population of tumor cells and overcome the immunosuppressive microenvironment of the 
tumor tissue. In advanced stages of the disease, immunotherapy should be combined with 
other treatment modalities that have the capacity to reduce the number of tumor cells, increase 
the sensitivity of tumor cells to the lysis by [CONTACT_781338].10,[ADDRESS_1074055] determined a time window after 
the chemotherapy when the T cells regain the capacity to be stimulated in the antigen specific 
manner and the protocol design reflects those findings.  
Induction of tumor specific T -cell-mediated immune response takes time and frequency of 
tumor -specific T-cells needs to be maintained by [CONTACT_781339]. This m echanism of action 
of cancer immunotherapy h as to be reflected in the clinical trial designs to ensure sufficient 
exposure of patients to the tested treatment. DCVAC/PCa should thus be administered over 
prolonged period of time, until the initiation of the next line treatment initiated for the 
confi rmed radiological progression to maximize its immunostimulating potential.  
 
 CONFIDENTIAL  Protocol No. SP005  
  EudraCT: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page 32 of 96 
 
DCVAC/PCa has been shown  to induce detectable tumor -specific immune responses in-vivo 
when administered concomitantly with docetaxel.15 From ongoing phase I/II trials t here is 
evidence that long -term application of DCVAC/PCa has an acceptable safety profile . Thus, 
there is a rational background that the chemo -immunotherapy approach of enhancing the 
immune response by [CONTACT_781340]/PCa with standard of care 
chemo therapy may have an impact on the survival benefit to subjects . DCVAC/PCa is being 
considered as an add -on option for subjects  requiring docetaxel  and as a maintenance boosting 
of immune system after docetaxel  treatment completion or discontinuation  to prolong OS .  
 
  
 CONFIDENTIAL  Protocol No. SP005  
  EudraCT: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page 33 of 96 
 
3 OBJECTIVES  
This is a Phase III confirmatory study to evaluate the overall survival superiority of treatment 
with DCVAC/PCa plus Standard  of Care ( docetaxel plus prednisone ) over placebo plus 
Standard of Care ( docetaxel plus prednisone ) in men with mCRPC .  
 
3.1 Study Objectives  
 
Primary:  
The primary objective is to show superiority of treatment with DCVAC/PCa in addition to 
Standard of Care chemotherapy  (docetaxel plus prednisone) over placebo in addition to 
Standard of Care chemotherapy  (docetaxel plus prednisone) in men with mCRPC as measured 
by [CONTACT_70112].  
 
Key Secondary:  
The key secondary objectives include assessments of safety, treatment group comparison with 
regards to Radiographic progression free survival  (rPFS) , time to prostate -specific antigen 
progression, time to first occurrence of skeletal related events (SRE) .  
 
Other Secondary:  
To show clinical benefit of treatment with DCVAC/PCa plus Standard of Care over placebo in 
addition to  Standard of Care with regard to time to radiographic progression or SRE, proportion 
of patients with skeletal related events (SRE ).  
 
Exploratory Objective:  
Treatment group comparison for the following measures:  
Proportion of subjects requiring second lin e treatment introduction and time to second line 
therapy , changes in quality of life (QoL)  and exploratory studies for search of potential 
biomarkers . 
 
3.2 Study Endpoints  
 
3.2.1 Primary Efficacy Endpoint  
Overall survival  is defined as the time from randomization until death due to any cause . 
 
3.2.2 Secondary Efficacy Endpoints  
 
The definitions of secondary en dpoints are based on the PCWG2 guidelines :29  
 
1. Radiological progression free survival  (rPFS)  
is defined as  the time from randomization to the date of earliest objective evidence of 
either:  
o radiographic progression of bone lesions  
or 
 CONFIDENTIAL  Protocol No. SP005  
  EudraCT: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page [ADDRESS_1074056] skeletal related events  
 
Other Secondary efficacy endpoints:  
• Time to radiographic progression or SRE  
• Proportion of patients with Skeletal Related Events (SRE)  
 
3.2.[ADDRESS_1074057] -P and 
EQ-5D (EQ -5D only in Europe) .  
 
Proportion of subjects requiring second line treatment introduction and time to seco nd line 
treatment introduction  will be evaluated . 
 
Exploratory studies for potential biomarkers will be performed to search for parameters that 
would indicate the biological effect of trial treatment or identify subjects  profiting from it.  
 
Additional exploratory studies may be conducted based on the future advances in the field of 
biomarker research.  
 
  
 CONFIDENTIAL  Protocol No. SP005  
  EudraCT: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page [ADDRESS_1074058] line chemotherapy  with docetaxel  plus prednisone , will be randomized 2:1 into one of two 
arms: an investigational arm (DCVAC/PCa) and a control arm  (placebo) in addition to Standard 
of Care chemotherapy (docetaxel plus prednisone ).  
 
If disease progression occurs on either arm of the study, the patient may be treated with 
subsequent therapy at the Investigator’s discretion  (see section 6.1.2 ). Administration of 
DCVAC/PCa  or placebo  will continue until start of second line treatment. DCVAC/PCa or 
placebo administrations can continue after documented Disease Progression until the 2nd line 
treatment is started .  
 
All subjects will receive up to 15 injections  of DCVAC/PCa or placebo or until refusal, 
intolerance, intro duction  of 2nd line treatment or death  occurs . All subjects  will also receive 
Standard of Care chemotherapy until refusal, intolerance, completion, disease progression, or 
death . DCVAC/PCa treatment will continue as a Maintenance Boosting Phase  after Standard 
of Care chemotherapy completion, refusal, intolerance o r discontinuation for other reasons. 
Subjects  may be treated with subsequent non -immunological therapi[INVESTIGATOR_713737]’s 
discretion until refusal, death or study closure .  
 
After screening (up to 28 days ) and within [ADDRESS_1074059] 
leukapheresis procedure.  For those randomized to receive DCVAC/PCa, PBMCs obtained by 
[CONTACT_781341]-vivo manipulation (up to 4 weeks). All subjects  
randomized to receive placebo injections will have a placebo prep ared. Manufacturing  
personnel, involved in  DCVAC/PCa or placebo  production process , and defined  investigational 
site unblinded team members (preparing the subcutaneous injections for both treatment arms) 
are the only persons that will not be blinded. All o thers associated with the study, including the 
apheresis center staff, will remain blinded to the randomization.  
 
Standard of Care chemotherapy (docetaxel  plus prednisone ) will begin 3 to 7 days after 
completion of leukapheresis.  DCVAC/PCa or placebo administration will begin approximately 
[ADDRESS_1074060] of Care chemotherapy.  DCVAC/PCa or placebo  is given as subcutaneous injections 
for up to 15 doses  following the study  schedule (see Table 1) or until refusal, intolerance,  
intro duction  of 2nd line therapy , or death.  Final analysis is planned when the target number of 
events is reached ( 657 deaths) which is anticipated to occur ap proximately [ADDRESS_1074061]: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page 36 of 96 
 
Figure 1: DCVAC/PCa Phase III study design  
 
 
  
[ADDRESS_1074062]: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page 37 of 96 
 
5 POPULATION  
Adult (age >18 years) men with histologically  or cytologicall y confirmed adenocarcinoma of 
the prostate with clinical or radiologic evidence of metastatic disease that has progressed despi[INVESTIGATOR_716107] (ADT) and who already prior to study entry are candidates to 
receive first line Standard of Care chemotherapy (docetaxel  plus prednisone ), will b e enrolled 
in this study.  A total of approximately 1,170 subjects  will be randomized at a 2:1 ratio to receive 
either DCVAC/PCa or placebo after introduction of the first line Standard of Care 
chemotherapy  with docetaxel  plus prednisone . 
 
5.1 Inclusion/Exclusion Criteria  
The Investigator or his/her designee shall  ensure that all  subjects  who meet the following 
inclusion and exclusion criteria are offered enrollment in the study.  
 
5.1.1 Inclusion criteria  
 Male 18 years and older.  
 Histologically or cytologically confirmed prostate adenocarcinoma.  
 Presence of skeletal, or soft -tissue/visceral/nodal metastases according to one of the 
following criteria:  
 Confirmed pathological fracture related to the disease  
OR 
 Confirmation of distant bone and/or soft -tissue and/or visceral metastases on CT or 
MRI scan or bone scintigraphy.  
 According to RECIST 1.1 a lymph node may be considered malignant if its short 
axis is ≥ 10 mm.  
 Note that presence of disease at the primary site alone is not considered 
metastatic di sease in accordance with PCWG2 and therefore not sufficient for 
entry.  
 Scans of the screening time point must be submitted to the image review facility 
(IRF) for confirmation of presence of metastases. The IRF will return a read 
result report which will pr evail over the site’s interpretation.  
OR  
 Positive pathology report of metastatic lesion.  
 Disease progression despi[INVESTIGATOR_781297]:  
 PSA increase that is ≥ 2 ng/mL and ≥ 25% above the minimum PSA as reached 
during ADT or above the pre -treatment level, if no response was observed and 
which is confirmed by a second value 1 or more weeks later.  
 
OR 
 Progression of measurable lymph nodes (s hort axis ≥ 15 mm) or visceral lesion 
measurable per RECIST v1.1 criteria30 (confirmation by [CONTACT_781327]);  
OR 
 Two or more new lesions appearing on bone scan/imaging compared with a previous 
scan (confirmation by [CONTACT_781327])  
 Maintenance of castrate condi tions: patients, who have not had a surgical orchiectomy, 
must continue with hormone therapy (GnRH/LHRH agonists or antagonists) to reach levels 
 CONFIDENTIAL  Protocol No. SP005  
  EudraCT: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page 38 of 96 
 
of serum testosterone of ≤ 1.7 nmol/L (50 ng/dL). The duration of the castration period 
must be at least 4 mont hs before screening as evidenced by [CONTACT_781342]/laboratory data (see section 6.8.1 ). 
 Laboratory criteria:  
 White blood cells (WBC) greater than 4,000/mm3  (4.0 x109/L) 
 Neutrophil count greater than 1,500/mm3 (1.5 x109/L). 
 Hemoglobin of at least 10 g/dL (100 g/L).  
 Platelet c ount of at least 100,000/mm3 (100 x 109/L). 
 Total bilirubin within normal limits (benign hereditary hyperbilirubinemias, e.g. 
Gilbert’s syndrome, are permitted).  
 Serum alanine aminotransferase, aspartate aminotransferase, and creatinine < 1.5x 
times the u pper limit of normal (ULN).  
 Life expectancy of at least 6 months based on Investigator’s judgment.    
 Eastern Cooperative Oncology Group (ECOG) Performance status 0 -2.  
 At least 4 weeks after surgery or radiotherapy before randomization.  
 A minimum of 28 days beyond initiation of bisphosphonate or denosumab therapy before 
randomization.  
 Recovery from primary local surgical treatment, radiotherapy or orchiectomy before 
randomization.  
 Signed informed consent including patient’s ability to comprehend its cont ents. 
 
5.1.2 Exclusion criteria  
 Confirmed brain and/or leptomeningeal metastases (other visceral metastases are 
acceptable).  
 Current symptomatic spi[INVESTIGATOR_781298].  
 Prior chemotherapy for prostate cancer.  
 Patient co -morbidities:  
 Subjects who are not indicated for chemotherapy treatment with first line Standard of 
Care chemotherapy (docetaxel and prednisone).  
 HIV positive, HTLV positive.  
 Active hepatitis B (active HBV defined in Section 7.6.8 ), active hepatitis C (HCV), 
active syphilis.  
 Evidence of active bacterial, viral or fungal infection requiring systemic treatment.  
 Clinically significant cardiovascular disease including:  
 symptomatic congestive heart failure.  
 unstable angina pectoris.  
 serious cardiac arrhythmia requiring medication.  
 uncontrolled hypertension.  
 myocardial infarction or ventricular arrhythmia or stroke within a 6 months 
before screening, known left ventricular ejection fraction (LVEF) < 40% or 
serious cardiac conduction system disorders, if a pacemaker is not present.  
 Pleural and pericardial effu sion of any NCI CTCAE grade.  
 Peripheral neuropathy having a NCI CTCAE ≥ grade 2.  
 CONFIDENTIAL  Protocol No. SP005  
  EudraCT: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page 39 of 96 
 
 History of malignant disease (with the exception of non -melanoma skin tumors) in the 
preceding five years.  
 Active autoimmune disease requiring treatment.  
 History of severe for ms of primary immune deficiencies.  
 History of anaphylaxis or other serious reaction following vaccination.  
 Known hypersensitivity to any constituent of the DCVAC/PCa or placebo product.  
 Uncontrolled co -morbidities including, psychiatric or social condition s which, in the 
Investigator’s opi[INVESTIGATOR_1649], would prevent participation in the trial.  
 Systemic corticosteroids at doses greater than 40 mg hydrocortisone daily or equivalent for 
any reason other than treatment of PCa within 6 months before randomization.  
 Ongoi ng systemic immunosuppressive therapy for any reason.  
 Treatment with anti -androgens, inhibitors of adrenal -produced androgens or other 
hormonal tumor -focused treatment performed on the day of randomization (except for 
GnRH/LHRH agonists or antagonists) to  exclude possible anti -androgen withdrawal 
response.  This criterion is not applicable to subjects who have never responded to anti -
androgen treatment, as there is no risk of anti -androgen withdrawal response.  
 Treatment with immunotherapy against PCa withi n 6 months before randomization.  
 Treatment with radiopharmaceutical within 8 weeks before randomization.  
 Participation in a clinical trial using non -immunological experimental therapy within 4 
weeks before randomization.  
 Participation in a clinical trial u sing immunological experimental therapy (e.g., monoclonal 
antibodies, cytokines or active cellular immunotherapi[INVESTIGATOR_014]) within 6 months before 
randomization.  
 Refusal to sign the informed consent.  
 
  
 CONFIDENTIAL  Protocol No. SP005  
  EudraCT: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page 40 of 96 
 
6 TREATMENTS  
 
6.1 Description of Treatments  
 
6.1.1 Study drug/placebo  
Durin g the concurrent treatment period , DCVAC/PCa or placebo is administered to the patient 
subcutaneously , every 3 weeks  (+/- 7 days) concurrently with Standard of Care chemotherapy . 
DCVAC/PCa or placebo will be administered at least [ADDRESS_1074063] dose of chemotherapy  (Day 8 -15 of chemotherapy cycle) .  
 
During the Maintenance Boosting period , DCVAC/PCa or placebo is administered to the patient  
every 4 weeks ( -7/+14 days) starting with the dose administered after the la st Standard of Care 
chemotherapy until a maximum of 15 doses  are administered  (the total number incl.  concurrent 
treatment period) .  
 
DCVAC/PCa is a cell -based immunotherapy consisting of DCs obtained from autologous 
monocytes cultured in the presence of GM-CSF and IL -4 and pulsed with the PCa cell line 
LNCaP killed by [CONTACT_781324] (HHP).  The tumor  cell–pulsed DCs are then 
activated by [CONTACT_52362] I:C, a Toll -like receptor 3 (TLR -3) ligand.  DCVAC/PCa induces an immune 
response against tumor  cells in-vivo. 
 
The safety profile of DCVAC/PCa is described in Section  1.3.2 . For additional  details refer to 
the IB.  
 
The placebo will be similar enough in appearance  and the syringe will be blinded adequately to 
prevent the patient and blinded staff from knowing the identity of the treatment. The placebo 
contains only freezing medium, the same used when producing DCVAC/PCa : CryoStor CS10. 
It is an aqueous, serum -free, animal  protein -free balanced electrolyte so lution, that includes 
various sugars, salts, and other components that provide pH buffering, oncotic/osmotic support, 
free radical scavenging, and energy substrates. It also contains 10% dimethylsulphoxide 
(DMSO).  It is manufactured according to GMP  with U SP grade components . 
 
It is unknown if the placebo will have AEs.  Subjects  in both treatment arms could have potential 
sensitivity reactions to the freezing medium.  
 
6.1.[ADDRESS_1074064] of Care chemo therap y (docetaxel plus prednisone ) 
and should reference the prescribing information provided with the product when treating the 
subjects . 
 
o Docetaxel in combination with prednisone  or equivalent is indicated for the treatment of 
subjects  with mCRPC.  The recommended dose of docetaxel is 75mg/m2 intravenous ly after 
reconstitution and dilution. Prednisone  5mg orally twice daily or equivalent is administered 
continuously.   
o All subjects  will receive Standard of Care chemotherapy (docetaxel  plus prednisone ) until 
completion, refusal, intolerance, disease progression, or death . 
 CONFIDENTIAL  Protocol No. SP005  
  EudraCT: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page 41 of 96 
 
 
Following discontinuation of docetaxel and study drug/placebo, all  subjects  may be treated with 
subsequent non -immunological therapy at the Investigator’s discretion  using the protoc ol 
defined list of treatment options:  
 
Defined list of second line treatment options  
The defined list of second line treatment options  allowed for use in mCRPC patients after 
docetaxel failure (in alphabetic order , based on NCCN guidelines, Version 2.2013 )30: 
abiraterone, cabazitaxel, docetaxel, enzalutamide, mitoxantron e, radium -223.  
 
 Abiraterone and enzalutamide  represents secondary hormonal manipulation and have 
shown survival benefit in clinical trials.  
 Cabazitaxel is cytotoxic chemotherapy that has shown survival benefit when used after 
docetaxel.  
 Radium -223 has shown survival benefit in patients with bone me tastas es and without 
visceral metastas es.  
 Docetaxel rechallenge can be used in patients who have not demonstrated definitive 
evidence of progression on prior docetaxel therapy.  
 Mitoxantrone has not demonstrated survival improvement in post -docetaxel use b ut 
remains a palliative option, particularly in men who are not candidates for cabazitaxel 
therapy.  
 
After failure of second line therapy, the selection of treatment options is at investigator’s 
discretion. There are some other cytotoxic agents that are used as a salvage therapy7(e.g. 
reintroduction of docetaxel, vinorelbine, vinblastine, doxorubicin, etc.). 
 
 
6.2 How The Study Drug is supplied  
 
6.2.1 Study drug/placebo  
Each individual dose of DCVAC/PCa or placebo is delivered to the study site in a temperature 
controlled shippi[INVESTIGATOR_781299] . Over the course of the study the site will receive up to  15 individual doses made 
specifically for a patient.  
 
Each individual dose contains 1mL of DCVAC/PCa or placebo in a cryovial sealed in a 
secondary package (plastic bag).  Each dose is produced for a specific patient and will be labeled 
accordingly.  
 
Thre e separate self-adhesive  labels  which are identical to the primary label  are included and 
will be used for labeling the syringe for administration  and documentation purposes.  
The completed IMP Administration Checklist is then provided  to the blinded study team 
member and this check list must be inserted into the source document ation  later (see section 
6.3.1  and IMP Administratio n manual).  
 
 CONFIDENTIAL  Protocol No. SP005  
  EudraCT: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page [ADDRESS_1074065] of Care therapi[INVESTIGATOR_781300].  
 
6.3 Storage, Preparation and Administration  
 
6.3.1 DCVAC/PCa / placebo  
 
Storage  
DCVAC/PCa or placebo will be transported to the clinical site frozen in liquid nitrogen vapors 
(referred to as  dry shipper) at a temperature below -150 °C or on dry ice at a temperature below 
-50 °C (referred to as thermo box) according to the clinical site location.   
 
After dilution, the DCVAC/PCa or placebo needs to be stored at room temperature  until 
administration .  
 
Preparation  
 
Prior to obtaining monocytes, patients were tested and found negative for HIV, HBV, HCV and 
Syphilis. DCVAC /PCa  and placebo treatment are sterile. Refer to the IMP Administration 
manual for detailed instructions regarding the product handling and preparation. Standard 
caution should be taken to protect the Investigational medicinal product (IMP) aliquot 
(DCVAC/PCa or placebo) from contamination when preparing for administration. 
DCVAC/PCa or placebo need to be handled and administered as standard sterile subcutaneous 
medicinal preparation.  
 
Administration  
 The subcutaneous injections must be admini stered within  [ADDRESS_1074066]  sunlight.  
 The subcutaneous injection is then divided into two 2.5 mL doses for better tolerability . 
Both injections  are given  in the lymph  node area  using  23 gauge  (0.6 mm)  subcutaneous 
injection needle . 
 Insert  complete d IMP Administration Checklist  into the  source  documentation .  
  
6.3.2 Study Drug Injection Sites   
The doses are repeated every 3 - 4 weeks (see Table 1) and should be rotated to an alternate 
anatomical area different to the previous injection, i.e. either right axillary area and left groin 
area or vice versa (for details see IMP Administrati on manual).  
6.3.[ADDRESS_1074067]: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page 43 of 96 
 
6.4 Patient Numbering   
Each patient is uniquely identified in the study by a “Subject ID” consisting of a protocol 
number  (SP005), the site number (Cxxx) and a subject  sequential number  (Bxxx) . The site 
number is assigned by [CONTACT_781343].  Upon signing the info rmed consent form 
(ICF), the patient is assigned a sequential subject number by [CONTACT_737]. At each site, the 
first patient is assigned patient number 1  (B001) , and subsequent subjects  are assigned 
consecutive numbers (e.g. the second patient is assigned patient number 2; the third patient is 
assigned patient number 3).  The Investigator or his/her staff will contact [CONTACT_21926] /IWRS  and 
provide the requested identifying information for the  patient to register him into the 
IVRS/IWRS . Once assigned to a patient, the subject number will not be re -used.  
If the patient fails to be found eligible after all screening procedures are complete, the 
IVRS/IWRS  must be notified within 3 days that the p atient will not be randomized and screen 
failure will be recorded in the source documentation . Subjects may undergo up to one additional 
screening for eligibility (re -screening, see Section  6.7.1 ). In such occasion the subject will get 
a new „Subject ID”.  
 
6.5 Treatment Assignment  
At Randomization visit , all eligible subjects  will be centrally randomized in a 2:1 DCVAC /PCa  
to placebo  allocation ratio via IVRS/IWRS . The randomization schedule is computer generated 
and will be stratified  by: 
 Region (US or other)  
 Prior therapy (abiraterone or enzalutamide or neither of the two)  
 ECOG status (0  - 1 or 2)  
Although, race is not used as a stratifying factor, special considerations will be given to include 
sites with a majority of African -American subjects  in order to ensure a representation of racial 
and ethnic groups.   
  
The treatment assignment will be gene rated using the following procedure to ensure that 
treatment assignment is unbiased.  A patient randomization list will be produced by [CONTACT_152472]/IWRS  provider using a validated system that automates the random assignment of 
treatment. The Investigator or his /her delegate will call or log on to the IVRS/IWRS  and confirm 
that the patient fulfills all the inclusion/exclusion criteria.  
 
Randomization assignment will be available to the SOTIO unblinded team members who are 
responsible for the drug manufacturing an d packaging.  Each package of study drug will contain 
the unique identification code containing  “Subject ID” and LOT number.  
 
6.6 Treatment Blinding  
Subjects , investigational site staff, personnel performing the assessments and monitoring, 
personnel performing leukapheresis, and data analysts will remain blind ed to the identity of the 
study treatment from the time of randomization until database lock, using the following 
methods:  
 
(1) Randomization data are kept strictly confidential until the time of unblinding, and will not 
be accessible by [CONTACT_781344]:  
 
 CONFIDENTIAL  Protocol No. SP005  
  EudraCT: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page 44 of 96 
 
 SOTIO personnel that coordinate and manufacture DCVAC/PCa  and placebo products .  
 Independent statistician who will prepare information for  IDMC.  
 IDMC members will routinely review blinded data, unless a safety signal has been 
identified and IDMC has decided to unblind the relevant cases to assess the signal.  
 Unblinded SOTIO pharmacovigilance personnel performing assessment of SAEs and their 
potential qualification as S[LOCATION_003]Rs and further distribution to regulatory bodies based on 
the treatment allocation.  
 Site staff receiving IMP dose from shipper and preparing the DCVAC/PCa or placebo for 
diluted and ready -to-inject form.  
 
(2) The identity of the treatments will be concealed by [CONTACT_781345] , the use of study drug/placebo that are identical in packaging, labeling, and 
schedule of administration.  The placebo will be similar enough in appearance and the syringe 
will be blinded adequately to prevent the patient and blinded staff from knowing the identity of 
the treatment.  
 
Unblinding will only occur in the case of patient emergencies (see Section 6.14), for regulatory 
reporting purposes and at the conclusion of the study.  
 
6.7 Patient Treatment Sequence  
 
6.7.1 Screen/Randomize  
All subjects  will be screened for eligibility to the study for up to [ADDRESS_1074068] met all of the 
inclusion and none of the exclusion criteria. Subjects  may undergo up to one additional  
screening for eligibility  (re-screening).  
   
6.7.2 Schedule leukapheresis procedure  
All subjects  will undergo an evaluation for leukapheresis by [CONTACT_781346] . This visit 
(or visits – if necessary) must be performed  prior to the leukapheresis procedure itself. The 
purpose of this visit is to assess technical aspects such as the patient’s venous access  (eventually 
a possibility to insert cen tral venous catheter) , to collect blood samples if required by 
[CONTACT_781347]/regulations and to provide further information to the patient regarding the 
procedure. Venous access check will be done by [CONTACT_781348]. Serological 
tests will be performed according to local regulations  in recommended timelines . Additional 
blood tests might be required per leukaphere sis facility requirements.  
Subjects  are not allowed to use ACE inhibitors 24 hours prior to leukapheresis. Calcium might 
be adminis tered to the patient as a precaution measure to supplement Ca2+ blood levels  during 
the leukaphere sis procedure . All leukapheresis  centers  will have been approved as part of the 
study.  The patient will be scheduled for the leukapheresis procedure to occur within [ADDRESS_1074069]: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page [ADDRESS_1074070] of potential complications can be 
found in the relevant  study manual s. The processing of the cells for the manufacturing of the 
DCVAC/PCa or placebo requires up to [ADDRESS_1074071] of Care chemotherapy plus DCVAC/PCa or 
placebo and consequently with DCVAC/PCa or placebo  alone  
Treatment period will consist of two parts. Concurrent treatment period - first line Standard of 
Care chemotherapy with docetaxel plus prednisone administered every 21 days will begin 3 to 
7 days after the leukapheresis procedure. The initial dose of DCVAC/PCa or placebo will be 
administered subcutaneously at least [ADDRESS_1074072] of Care (d ocetaxel plus prednisone ) will be given in 3 week intervals (+/ - 7 days).  
DCVAC/PCa or placebo will be administered at least [ADDRESS_1074073] o f Care chemotherapy is completed or discontinued, DCVAC/PCa or placebo 
will be given  in Maintenance Boosting  period. Frequency of DCVAC/PCa or placebo 
application will continue  in 4 week intervals with an acceptable window of - 7/+[ADDRESS_1074074] dose of DCVAC/PCa or placebo, the patient will be observed for 2 hours in a 
supervised out-patient setting for AEs.  For the second dose and all subsequent doses of 
DCVAC/PCa or placebo administration the patien t will be observed for at least [ADDRESS_1074075] 1.1 criteria.31 Additionally, cur rently used immunological treatments 
(e.g., ipi[INVESTIGATOR_125]) tend to show that despi[INVESTIGATOR_781301] a higher 
chance for the subjects  to gain prolongation of survival.  For these reasons, the application of 
DCVAC/PCa or placebo wil l continue irrespective of progression , however, it must be 
discontinued  at the moment of  introduction of 2nd line antitumor  treatment . Following a 
confirmed documented radiological progression, Standard of Care chemotherapy will be 
discontinued and t he second line treatment may be introduced at the Investigator’s discretion  
using the protocol defined list of second line treatments (see section 6.1.2 ).  
 
 
 
 
 
 CONFIDENTIAL  Protocol No. SP005  
  EudraCT: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page [ADDRESS_1074076] continue with hormone therapy 
(GnRH/LHRH agonists or antagonists) to reach levels of serum testosterone ≤  1.7 nmol/ L (≤ 
50 ng/dL). The duration of the castration period (orchiectomy or GnRH/LHRH agonist s or 
antagonists) must be at least [ADDRESS_1074077] GnRH/LHRH analog administration mo re than 6 months before screening, 
and serum testosterone level ≤ 1.7 nmol/ L measured either more t han 4 months before screening 
or at screening. Secondary hormonal manipulation , if used  (e.g. abiraterone, enzalutamide) , 
must be discontinued on the day of randomization at the latest  and may be introduced only after 
DCVAC/PCa  or placebo  is discontinu ed.  
 
6.8.[ADDRESS_1074078] be 
available at sites, where application of DCVAC/P Ca or placebo is performed.  
 
Investigators should comply with institutional standards of care in managing subjects  who 
exhibit life -threatening symptoms while receiving treatment under this protocol. Specific 
country references to Resuscitation Guidelines such as those for the [LOCATION_006] found on the web site 
http://www.resus.org.uk/pages/guide.htm #updates  are recommended.  
 
 
Subjects  having a  serious  allergic reaction to DCVAC/PCa or placebo must be withdrawn from 
the treatment phase of the study.   
 
6.8.[ADDRESS_1074079] the patient to notify the study site about any new medications 
taken from screening . All medications and significant non -drug therapi[INVESTIGATOR_014] (including physical 
therapy and blood transfusions) administered after screening must be listed on the Concomitant 
Medications/Significant Non -drug Therapi[INVESTIGATOR_14932].  Active immunization with anti -infectious 
vaccines when appropriately indicated is allowed according to prescribing information as well 
as administration of intravenous immunoglobulins for the correction of s econdary 
hypogammaglobulinemia.  
 
6.8.4 Prohibited Medications  
Prohibited medications include:  
 
 Systemic immuno -suppressive therapy, including systemic corticosteroids at doses 
greater than 40  mg of hydrocortisone daily or equivalent, for any reason other than the 
treatment of prostate cancer.  
 Immunotherapy with other approved medications including monoclonal antibodies, 
active cellular therapi[INVESTIGATOR_781302].  
 Other investigational medicinal products.  
 CONFIDENTIAL  Protocol No. SP005  
  EudraCT: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page 47 of 96 
 
 Concomitant anti -androgens other than GnRH/LHRH agonists or antagonists for 
maintaining castrate condition .  
 ACE inhibitors 24 hours prior to leukapheresis.  
 Concomitant  use of  alpha particle -emitting radioactive therapeutic agent (e.g. radium -
223), or other radioactive isotopes indicated for systemic treatment of b one metastas es. 
 
6.[ADDRESS_1074080] line chemotherapy  (docetaxel plus prednisone ) will be 
performed according to the approved prescribing information provided with the product.  The 
recommended dose of docetaxel is 75 mg/m2. Prednisone  or prednisolone 5 mg orally twice 
daily  (or equivalent)  is administered continuously. Docetaxel should be administered when the 
neutrophil count is ≥  1,500 cells/mm3. In patients who experienced either febrile neutropenia, 
or neutrophil count < 500 cells/mm3 for more than one week, or severe or cumulative cutaneous 
reactions , or severe peripheral neuropathy during docetaxel therapy, the next dose of docetaxel 
should b e reduced from 75 mg/m2 to 60 mg/m2. If the patient continues to experience these 
reactions at 60 mg/m2, the treatment should be discontinued.  All changes in dosage must be 
recorded in the eCRF.  
 
For the study drug DCVAC/PCa or placebo , the full dose will be administered across all 
applications and dosing modification  is not applicable. Each  dose during  the Concurrent 
Treatment period will be administered between two chemotherapy cycles and the gap between 
DCVAC/PCa or placebo and previous an d subsequent chemotherapy must be at least 7 days. If 
the chemotherapy application is delay ed for any reason, DCVAC/PCa or placebo will be 
administered at least [ADDRESS_1074081] chemotherapy  administration . In case of acute 
infection or fever, DCVAC/P Ca or placebo application has to be postponed until patient has 
recovered from the condition. When interruption of treatment is needed, DCVAC/PCa or 
placebo is allowed to be re -introduced within 12 weeks.  
 
 
6.10 Study drug discontinuation/End of Treatment  
Subjects are expected to remain on study treatment until completion or until introduction of 2nd 
line antineoplastic therapy . After discontinuation for any reason or completion of all doses of 
DCVAC/PCa or placebo  per protocol, subjects should be considere d off -DCVAC/PCa or 
placebo treatment and to be evaluated at the next regularly scheduled visit  within [ADDRESS_1074082] dose of DCVAC/PCa or placebo  (End of Treatment Visit).  It is highly recommended to 
evaluate disease progression prior to introduction of 2nd line antineoplastic therapy if the 
decision is made before completion of study treatment.  
 
Maximum  gap between two consequent DCVAC /PCa  or placebo administration s should not 
exceed 12 weeks. If interruption  of DCVAC /PCa  or placebo lasts  for more than [ADDRESS_1074083]: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page 48 of 96 
 
All randomized patients who  subsequently permanently discontinue the treatment, will still be 
followed up according to section 6.12 (even if the subject discontinued for the following 
reasons ): 
 Emergency unblinding of treatment assignment when investigator or patient are 
unblinded (see section 6.14). 
 Protocol violation requiring patient withdrawal as assessed by [CONTACT_223493].  
 Patient unable to tolerate the leukapheresis procedure . 
 Failure to pr oduce DCVAC/PCa or placebo in the Sponsors manufacturing facilities.  
 Patients having a serious allergic reaction to DCVAC/PCa or placebo must be 
withdrawn from the treatment phase of the study.  
 
6.[ADDRESS_1074084] 
dose of treatment  (End of Treatment  Visit)  up to [ADDRESS_1074085] not received DCVAC/PCa 
or placebo for other reasons,  will be followed up for survival  only. The survival data will be 
collected every [ADDRESS_1074086]  (or a relative/caretaker) . Subjects 
who discontinue either DCVAC/PCa or placebo treatment should enter the follow -up phase of 
the study. See Table 1 for the required assessments for these subjects during follow -up. If 
applicable, subjects should continue on 2nd line antineoplastic therapi[INVESTIGATOR_014]  (see section 6.1.2 ) for 
prostate cancer and then other therapi[INVESTIGATOR_014] . All randomized  patients will remain in the  study and 
will be followed until ICF withdrawal, death or study closure regardless their future treatment 
and /or participation in different clinical trials.  Final analysis will be performed  upon reaching 
the targeted number of events . If subject refuses to return to the site for follow/up assessment, 
the investigator will make every effort to contact [CONTACT_423] (or a relative/caretaker) to collect 
survival information. The investigator should show “due diligence” by [CONTACT_781349], i.e., dates of telephone calls, registered 
letters, etc.  
 
6.13 Premature patient withdrawal / End of Study  
Subjects  may voluntarily withdraw from the study  or be discontinued at the discretion of the 
Investigator at any time . If such withdrawal occurs, or if the patient fails to return for visits, the 
Investigator shall determine the primary reason for a patient’s premature withdrawal from the 
study and record this information on the End of Study eCRF and notify the IVRS/IWRS .  
 
Subjects  must  be withdrawn  from the study prematurely for one of the following reasons:  
 Informed consent withdrawn  for continued study participation . 
 Death.  
 
 CONFIDENTIAL  Protocol No. SP005  
  EudraCT: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page [ADDRESS_1074087] the patient and determine the primary reason for a patient’s premature withdrawal 
from the study and record this information on the End of Study eCRF. The End of Study visit 
assessments should be performed wherever possible; however, at a minimum , subjects  will be 
contact[CONTACT_5365] a safety evaluation assessment up to [ADDRESS_1074088] often, study drug discontinuation and knowledge of the possible 
treatment assignments are sufficient to treat a study patient who presents with an emergency 
condition.  Emergency code breaks are performed using the IVR S/IWRS. The study medical 
monitor will be contact[CONTACT_781350], wherever possible, and when the patient’s safety 
is not compromised. When the Investigator contacts the system to unblind a patient, he/she must 
provide the requested patient identifyin g information and confirm the necessity to unblind the 
patient.  The Investigator will then receive details of the drug treatment for the specified patient 
and a fax or email confirming this information.  The system will automatically inform the 
SOTIO repres entatives that the code has been broken . 
 
There may be instances where unblinding may be required for a safety review at the request of 
the IDMC or for a Regulatory Authority.  If this is not considered to be emergency unblinding, 
the assigned treatment is not revealed to the site Investigator, the study Principal Investigator, 
or the clinical or data management staff of the Sponsor or the CRO, the patient will continue 
with study treatment until protocol criteria for withdrawal are met .  
 
  
 CONFIDENTIAL  Protocol No. SP005  
  EudraCT: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page 50 of 96 
 
7 VISIT SCHEDULE AND ASSESSMENTS  
 
Screening Period  
All subjects  will be evaluated for inclusion in the study during the Screening Period. Procedures 
to be performed are described in  Table 1.   
 
Randomization Visit  
At the day of Randomization Visit subjects  will be re -evaluated for inclusion in the study, 
relevant tests and safety information will be collected (see  Table 1) and subjects  who are eligible 
for the study based on screening assessments  will be randomized on Day 1 as described in 
Section 6.5.  
 
Leukapheresis Evaluation and Leukapheresis Timeline  
Per section 6.7.2  and prior to the leukapheresis  (not more than 7 days where required by [CONTACT_781351])  procedure  all subjects  will undergo leukapheresis evaluation 
(laboratory  tests and vein access check) . Laboratory tests must be performed according to local 
law and regulations.  All subjects  will undergo leukapheresis procedure  within [ADDRESS_1074089] of Care chemotherapy  
with docetaxel plus prednisone  plus DCVAC/PCa or placebo every [ADDRESS_1074090] line chemotherapy (docetaxel and prednisone ) and DCVAC/PCa 
treatment will be added after the second cycle of docetaxel.  
 
The end of the  Concurrent Treatment Period starts  when the first line Standard of Care 
chemotherapy has been discontinued for any reason.   
 
Maintenance  Boosting Period   
During the Maintenance Boosting Period subjects  will continue to receive DCVAC/PCa or 
placebo every 28 days until completion of all manufactured 15 doses  or refusal, intolerance,  
intro duction  of 2nd line treatment  or death. Based on the Investigator’s decision, the second line 
Standard of Care therapy may be introduced if considered to be beneficial.  DCVAC/PCa 
administration must be discontinued in this case.  The end of the  Maintenance  Boosting Period 
starts when t he DCVAC/PCa or placebo treatment has been discontinued for any reason.  
 
End of Treatment  
The End of study treatment visit to be done within [ADDRESS_1074091] application of 
DCVAC/PCa or placebo . 
 
Follow -up Period  
During the Follow -up period subjects  will be off the DCVAC/PCa or placebo treatment but 
may continue Standard of Care therapy.  Subjects  are followed until refusal, death or study 
 CONFIDENTIAL  Protocol No. SP005  
  EudraCT: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page [ADDRESS_1074092] has a documented date of death.  
 
The Visit Evaluation Schedule ( Table 1) lists all of the assessments and indicates with an “X” 
the visits when they are performed.  All data obtained from these assessments must be supported 
in the patient’s source documentation.  Assessments that are transferred to the database 
electronically (e.g. laboratory  data) are listed by [CONTACT_655169].  Please note that the Visit Evaluation 
Schedule indicates visits and evaluations to be performed under ideal circumstances. For some 
assessments ( e.g. PSA and CT/MRI/bone scan), the interval between evaluations (e.g. 12 
weeks) should be observed if the visit schedule is modified for any reason. Therefore, such 
assessments might be performed at other visits than shown here.   
 CONFIDENTIAL  Protocol  No. SP005  
 EudraCT: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page 52 of 96 
 
Table 1: Visit Evaluation Schedule  
 
 
Study period  
Screening  
Randomization  
Leukapheresis  Concurrent Treatment  Period * Maintenance  Boosting Period† 
EOT1 
Follow Up  
EOS2 
3 week cycles  4 week cycles  
4Weeks  
12 week 
cycles  
4 weeks  
Cycle  1 2 3 4 5 6 7 8 9 10 1 2 3 4 5 6 
Week of Cycle  1 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 1 1 1 1 1 
Informed consent  X                               
Treatment Assignment   X                              
Demographic data  X                               
Medical history  X                               
Hematology  X X  X X  X  X  X  X  X  X  X  X  X X X X X X X   
Biochemistry  
(incl. ALP, LDH)  X X  X X  X  X  X  X  X  X  X  X  X X X X X X X   
PSA3 X X       X        X      X   X   X X3  
TSH  X        X        X      X   X   X   
Urinalysis  X X  X   X    X    X    X    X   X   X   
HIV, syphilis, HTLV , 
Hepatitis B and C  X  X5                             
Testosterone  X16                               
aPTT / Quick  (PT) X                               
Full PE and height  X                               
Symptom directed PE   X  X X X X X X X X X X X X X X X X X X X X X X X X X X   
Vital signs & weight  X X  X X X X X X X X X X X X X X X X X X X X X X X X X X X  
ECOG score  X X  X X X X X X X X X X X X X X X X X X X X X X X X X X X  
 CONFIDENTIAL  Protocol  No. SP005  
 EudraCT: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page 53 of 96 
 
 
Study period  
Screening  
Randomization  
Leukapheresis  Concurrent Treatment  Period * Maintenance  Boosting Period† 
EOT1 
Follow Up  
EOS2 
[ADDRESS_1074093] -P questionnaire  X   X   X    X    X    X    X X X X X X X   
EQ-5D questionnaire 
(only in Europe)  X      X        X18        X18   X18   X18 X18  
Samples for research6  X           X                X   
Leukapheresis 
evaluation7   X4                             
Leukapheresis 
procedure8   X                             
DCVAC/PCa  or placebo 
in process    X X X                           
First line 
chemotherapy9,*    X X  X  X  X  X  X  X  X  X           
DCVAC/PCa  or placebo 
s.c.injection10,†      X  X  X  X  X  X  X  X  X X X X X X X11    
Adverse Events  X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X12 X12 
Documentation of any 
SRE  X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X 
Disease assessment14 
CT(MRI13)/bone scan X15        X        X      X   X    X14  
Concomitant 
Medications   X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X 
Survival Follow -up17                              X X 
*The first line chemotherapy may be discontinued early if subject refuses or has intolerance. Subjects are then eligible to c ontinue in the Maintenance Boosting period, 
receiving DCVAC/PCa or placebo as monotherapy in [ADDRESS_1074094]: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page 54 of 96 
 
†When subjects finish or stop receiving DCVAC/PCa or placebo, they complete the End of Treatment procedures within [ADDRESS_1074095] dose of the  study drug (End 
of Treatment Visit) and enter the Follow -up period.  
1 End of Treatment (EOT) visit procedures  are performed within 30 days after discontinuation of DCVAC/PCa or placebo . 
2 End of Study (EOS) visit procedures are performed within 30 days after premature withdrawal  for ICF withdrawal, death, or study closure . 
3 Until progression, introduction of 2nd line therapy or end of clinical trial, every 12 weeks . 
4 Vein access check at investigational site or by [CONTACT_781348] . 
5 Per local regulations for infectious diseases (HBV, HCV, HIV, HTLV, syphilis ) as applicable . Additional blood tests might be required per apheresis cent er requirements.  
6 Blood sample for research purposes to be taken at randomization, before  administration of the 5th dose of DCVAC /PCa or  placebo, at EOT visit. 
[ADDRESS_1074096] begin  3 to 7 days after leukapheresis.  
10 The subcutaneous injection of DCVAC/PCa or placebo must be given at least  [ADDRESS_1074097] of care chemotherapy.  
11 Until total number of 15 doses of DCVAC/PCa / placeb o, depending on number of first line chemotherapy cycles; until introduction of 2nd line chemotherapy  
12 Serious Adverse Reactions ( SARs ) and Adverse Events of Special Interest (AESIs)  with a plausible causal relationship to investigational product . 
[ADDRESS_1074098] medium and the ab domen and pelvis should be imaged using 
MRI.  
14 Imaging will be performed every 12 weeks as close  as possible  to the PSA sampling until radiological progression, introduction of 2nd line therapy or end of clinical 
trial. 
15 Not earlier than 28 days before screening, and  preferably  not later than 14 days before randomization  to allow for timely confirmation of radiographic eligibility  by 
[CONTACT_18014] . 
16 To be measured in case that historical ( older than 4 months before screening ) serum testosterone value doesn´t exist.  
[ADDRESS_1074099] not received DCVAC/PCa or placebo for other reasons , will be  followed up for survival only  
[ADDRESS_1074100]: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page 55 of 96 
 
7.1 Patient Demographics/Other Baseline  Characteristics  
Screening evaluations will occur in a period of up to [ADDRESS_1074101] screening evaluation 
to randomization unless otherwise specified.  The purpose of the screening period is to assure 
that subjects  meet all entry criteria and that they adequately comprehend the protocol and its 
requirements.  More than one clinic visit may be required in order to complete all screening 
evaluations.  
 
The screening/baseline procedures will collect the following inform ation:  
 
 Disease History:   
o Histological or cytological diagnosis of prostate adenocarcinoma.  
o Date of initial diagnosis.  
o Staging, Gleason score and PSA level at initial diagnosis.  
o Two last historical PSA values before screening including dates  
o Details of primary treatment for prostate cancer including dates of therapy 
(radiation, surgery, steroids and/ or hormones), prior use of sipuleucel -T, abiraterone  
and enzalutamide . 
o Physician’s assessment of progression of disease to qualify for study.  
o Castrat ion history and duration of treatment before screening . Serum testosterone 
level must be measured at screening in case that historical (older than 4 months 
before screening) serum testosterone value doesn´t exist. In such case investigator 
must document that pat ient started GnRH/LHRH analogs more than 6 months before 
screening.  
o Bisphosphonate or denosumab  or opi[INVESTIGATOR_781303].  
o History/baseline of SRE.  
 Patient Demographics – age, ethnicity, race.  
 Life expectancy based on investigator’s judgment.  
 Medical history – significant historical events or findings and any pre -existing 
conditions – history of anaphylaxis or other serious reactions following vaccination, 
history of severe forms of primary im mune deficiencies.  
 Physical exam – concurrent illness, height, weight, vital signs (blood pressure, heart rate 
and temperature), peripheral neuropathy, pleural and pericardial effusions.  
 Eastern Cooperative Oncology Group (ECOG) Performance Status, Quality  of life 
(QoL) questionnaires FACT -P and EQ -5D (EQ -5D only in Europe) . 
 Disease assessment by [CONTACT_4654], bone scan (historical scans  can be up to 2 years old , 
screening scans can be performed within additional 4 weeks before  screening period 
starts , only if result s can be forwarded for central review).  
 Hematology and Biochemistry including LDH, ALP, TSH  and PSA.  Urine analysis will 
be performed.  
 HIV, HTLV, syphilis, HBV and HCV status.  
 Vein access check  at investigational site  or by [CONTACT_781348].  
 
 CONFIDENTIAL  Protocol No . SP005  
  EudraCT: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page [ADDRESS_1074102] of Care therapy treatments will be recorded in the  eCRFs documenting date of therapy, 
dosage, route of administration, and reasons for dose modifications and discontinuation.  
DCVAC/PCa or placebo treatment will be recorded in the eCRFs documenting date and time 
of therapy and site of injection.  Hypersensitivity reactions or other untoward events will be 
recorded in the AE eCRF page.   
 
7.3 Efficacy  
Trial objectives and outcomes include OS, Radiographic progression free survival (rPFS) , Time 
to PSA progression , Time to first skeletal related events  and proportion of patients with  skeletal 
related events .  
 
1. Overall survival (OS)  is defined as the time from randomization until death due to any 
cause. Overall survival can be determined by [CONTACT_781352], death certificates, and/or hospi[INVESTIGATOR_307]/clinic records indicating date of death 
and source of information.  
 
2. Radiological progression free survival  (rPFS)  
is defined a s the time from randomization to the date of earliest objective evidence of 
either:  
a. radiographic progression of bone lesions  
or 
b. radiographic progression of soft tissue lesions  
or 
c. death due to any cause  
 
3. Time to PSA progression is defined as the time from  randomization to the date of 
earliest objective evidence of PSA progression . 
 
4. Time to first skeletal related events is defined as the time from randomization to the 
date of first skeletal related events. Proportion of patients with skeletal related events  
is defined as the proportion of patient after randomization  
 
 
7.3.1 Prostate -specific antigen  
PSA levels will be assessed every 12 weeks (+/ -7 days) as close as possible  to imaging 
assessments  (see Visit Evaluation Schedule, Table 1).  
 
The evidence of  PSA progression is defined as: time from randomization to the date of PSA 
absolute increase ≥ 2 ng/mL and ≥ 25% above nadir or baseline values confirmed by a second 
consecutive value obtained at least [ADDRESS_1074103]: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page 57 of 96 
 
7.3.2 Soft Tissue and Bone Lesions  
[IP_ADDRESS]  Schedule of Imaging Time points  
Imaging will be performed at screening ( not earlier than 28 days before screening, and  
preferably  not later than 14 days before randomization  to allow for timely confirmation of 
radiographic eligibility by [CONTACT_18014] ) and after randomization at 12 week (±7 days) 
intervals . Confirmation of imaging progression is required  on a follow -up imaging time point  
at earliest 6 weeks later, preferably at the following regular imaging time point  date, if the 
progression occurs at week 12  and 24 . After confirmation of radiological progression or after 
introduction of 2nd line therapy , no more imaging examinations of the patient  will be required 
for this trial . 
  
If the patient did not progress but was removed from study treatment  (EOT) , the every 12 week 
schedule (+/ -7 days) for imaging assessment will be followed until progression , introduction of 
2nd line therapy  or end of clinical trial  to assess radiological progression . It is highly 
recommended to evaluate disease progression prior to introduction of 2nd line antineoplastic 
therapy if the decision is made before completion of stu dy treatment.  
[IP_ADDRESS]  Mandatory Imaging Modalities at Each Imaging Time point  
 Contrast (intravenous and oral) enhanced spi[INVESTIGATOR_781304], abdomen and pelvis  
o In case of sensitivity to i.v. contrast medium, the CT chest scan should be performed 
without i.v. con trast medium and the abdomen and pelvis should be imaged using 
MRI.  
o Positive oral contrast media (iodine or barium) is preferred over negative oral 
contrast media (pure water or solutions of mannitol  or methylcellulose).  
 Technetium bone scan of the whole b ody 
 
Ultrasound is not accepted for tumor evaluation. Note that the same imaging techniques must 
be used at all time points .  
 
An imaging guidance document will be provided to the sites for a detailed description of the 
imaging procedures.  
[IP_ADDRESS]  Site Radiologist  
All scans obtained from all subjects  enrolled at each site should be reviewed by [CONTACT_781353].   
If possible, the same radiologist/physician should perform the evaluation for the entire duration 
of the study.   
[IP_ADDRESS]  Image Review Facility (IRF)  
All study defined imaging data must be sent to the IRF immediately after acquisition.  
 CONFIDENTIAL  Protocol No . SP005  
  EudraCT: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page 58 of 96 
 
The IRF will quality control the imaging data quality and review them for respon se and 
progression.  
The specifics of the review procedure will be described in a separate Imaging Charter.  
[IP_ADDRESS]  Review  of Bone and Soft Tissue Disease  
Bone and Soft Tissue Disease will be evaluated for Progression according  to the Prostate Cancer 
Working Group 2 (PCWG2) recommendations for clinical trial conduct in castration -resistant 
disease.29 The following m inor modifications will be applied to the PCWG2 criteria:  
 Progressive disease (PD) of bone or soft tissue les ions must be confirmed on a second scan 
at earliest 6 weeks later, preferably at the following regular imaging time point  date if the 
progression occurs at week s 12 and 24  
 Progressive disease (PD) of soft tissue lesions will be assessed using modified RECI ST 1.[ADDRESS_1074104] 6 
weeks later, preferably at the following regular i maging time point  date.  
 If at the first [ADDRESS_1074105] two additional new lesions on the confirmatory scan.  
 If at the [ADDRESS_1074106] 1.131 with the following 
modifications :  
 Nodal disease:  To be considered a new malignant node or a measurable node, the 
short axis must be ≥  [ADDRESS_1074107] diameter ≥  20 mm. 
 Disease in the prostate bed is defined as non -measurable disease . 
 PD of Soft Tissue Lesions has to be confirmed by a confirmatory scan performed at 
earliest [ADDRESS_1074108]  1.1 rules and definitions to be used in this study are listed below:  
 Measurable disease at baseline  
 Threshold for lesion measurability : 
The minimum diameter which can be reproducibly measured is twice the 
reconstruction interval. For spi[INVESTIGATOR_781305] ≤  [ADDRESS_1074109]: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page 59 of 96 
 
the value is 10  mm. If larger reconstruction intervals are used (not 
recommended), the threshold value increases accordingly.  
 Visceral disease  
o Longest diameter ≥  10 mm.  
o Disease in the prostate bed is defined as non -measurable disease 
irrespective of its s ize. ( modification to RECIST  1.1) 
 Nodal disease  
o short axis ≥  [ADDRESS_1074110] diameter ≥  20 mm ( modification to RECIST  1.1) 
 Non-measurable disease at  baseline  
 Visceral disease  
o Any lesion too small to be measurable disease.  
o Truly non -measurable lesions: leptomeningeal disease, ascites, 
pleural or pericardial effusion,  lymphangitic involvement of skin or 
lung.  
o Disease in the prostate bed is defined as non -measurable disease. 
(modification to RECIST  1.1) 
 Nodal disease  
o Any pathological lymph node with a short axis ≥  10 mm but too small to 
be measurable disease.  
 New Lesions  
The finding of new lesions on follow -up time points  should be unequivocal.  
For lymph nodes to be considered new disease the following size criteria will 
apply:  
o short axis ≥  15 mm ( modification to RECIST  1.1) and  
o longest diameter ≥  20 mm ( modification to RECIST  1.1) 
 
A short summary of the RECIST 1.[ADDRESS_1074111] 1.1 publication.31 
 At baseline all l esions are classified either as target or as non -target lesions to 
estimate the baseline tumor burden.  
 Target lesions are a subset of measurable lesions.  
Up to a maximum of 5 lesions in total and a maximum of 2 per organ are 
selected and measured.  
The bas eline sum of diameters (longest for non -nodal lesions, short axis for 
nodal lesions) will be calculated.  
 Non-target lesions are all other lesions.  
Non-target lesion s will have their location reported. Their size does not 
contribute to the sum of diameters . 
 At each follow -up time point  each lesion category  will be evaluated for 
progression or non -progression  
 Target lesion  Progressive Disease (PD):  
 CONFIDENTIAL  Protocol No . SP005  
  EudraCT: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page [ADDRESS_1074112] a 20% increase in the sum of diameters, taking as reference 
the smallest sum on study (this is not necessarily the baseline sum 
diameters). In addition to the relative increase of 20%, the sum must 
also demonstrate an absolute increase of at least 5 mm.  
 Non-target lesion  Progressive Disease (PD ) 
o Unequivocal progression of existing non -target lesions.  
 New Lesion:  
o The appearance of one or more new lesions is considered progressi ve 
disease  (PD).  
 For each follow -up time point  the response outcome for each lesion category will 
be combined to an overall time point  response as illustrated in the table below.  
 
Target Lesions  Non-target Lesions  New Lesions  Overall Response  
Non-PD Non-PD No Non-PD 
PD Any Yes or No  PD 
Any PD Yes or No  PD 
Any Any Yes PD 
 
 
7.3.3 Skeletal related events  
Skeletal related events include:  
• radiation therapy to bone,  
• pathologic bone fracture,  
• spi[INVESTIGATOR_13377],  
• surgery to bone or  
• change in antineoplastic therapy to treat bone pain.  
 
 
7.[ADDRESS_1074113]: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page 61 of 96 
 
effusion related to metastatic disease , fatigue , unintentional weight loss, progressive anemia  
that cannot be explained due to any other reason , these shou ld be carefully documented.  It is 
highly recommended to evaluate objective disease progression (bone and soft tissue lesions as 
per Section 7.3.2 ) prior to introduction of 2nd line antineoplastic therapy if the decision is made 
before completion of study treatment.  
 
In the absence of other indicators of disease progression, antineoplas tic therapy should NOT be 
switched solely on the basis of a rise in PSA.   
 
7.6 Safety  
Safety evaluations will include safety laboratory and immunological assessments, clinical 
evaluation of vital signs, physical examinations, performance status using ECOG scale, 
radiological examinations, and recording of all AEs. 
 
7.6.1 Adverse events  
An AE is t he appearance of (or worsening of any pre -existing) undesirable and unintended sign 
(e.g. tachycardia, enlarged liver), symptom (e.g. nausea, chest pain), or the abnormal results of 
an investigation (e.g. laboratory findings)  occurring after signing the informed consent  till [ADDRESS_1074114] dose of DCVAC/PCa or placebo (EOT)  even if the event is not considered 
to be related to the study drug(s) or procedure(s).   
 
The definition used by [CONTACT_781354] p rovided in 
ICH E2A standard:  
 
“Any untoward medical occurrence in a patient or clinical investigation subject administered a 
pharmaceutical product and which does not necessarily have to have a causal relationship with 
this treatment.”  
 
All Investigators s hould follow the protocol and the local regulation s. The attending physician 
is responsible for describing, diagnosing and treating all AEs in accordance with the best 
standards of medical care.  
 
Please refer to Section 6.1 and 7.2 for the protocol -specific definitions of study drug and study 
procedures.  
 
AEs will be assessed according to the NCI Common Toxicity Criteria for Adverse Events 
(CTCAE) version 4.[ADDRESS_1074115] for an AE, the severity of mild, 
moderate, severe, life -threatening  and death , or grades 1 – 5, will be used.  
 
AEs occurring before starting study treatment but after signing the ICF are  also collected and 
recorded on the Advers e Event eCRF. This includes AEs observed before , during and after 
study procedures (e.g. screening, leukapheresis).  All SAEs must be additionally documented 
on a “Serious Adverse Event Report Form”.  
 
 CONFIDENTIAL  Protocol No . SP005  
  EudraCT: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page [ADDRESS_1074116] results constitute AEs only if they are considered 
clinically significant, in particular if accompanied by  [CONTACT_148459], require 
therapy or another medical intervention (e.g. hypokalemia  that requires saline substitution ), lead 
to ch ange in medication dosing or administration,  or require that  the patient change s the study 
schedule . Abnormal hematological laboratory values should be recorded on the Adverse Events 
eCRF under the signs, symptoms or diagnosis associated with them  (e.g. ne utropenia, Grade 2) . 
In case that laboratory value  or vital sign is a sign of a medical condition, the condition should 
be reported as an AE and not the sign.  
  
Surgical procedures are not AEs but therapeutic measures for conditions that require surgery . 
Therefore , the condition for which the surgery is required has to be reported as an AE.  Pre-
planned surgery  (before  signing off ICF ) or other interventions permitted by [CONTACT_781355].  
 
The occurrence of AEs will be recorded on an ongoing basis and patients will be asked 
specifically whether they have noticed any unexpected or unusual symptoms at each scheduled 
or unscheduled visit s. AEs also may be detected when they are volunteered by t he patient during 
or between visits or through physical examination, laboratory test, or other assessments.  Reports 
from patient relatives or caregivers should be recorded , once verified .  
 
If possible, each AE should be evaluated to determine:  
 AE term or description  of the AE in medical terms (not as reported by [CONTACT_102])  
 The severity grade ( grade 1 -5 as listed in NCI CTCAE v4.03)  
 Its causal  relationship to the IMP, first line chemotherapy (suspected/not suspected)  and 
study procedure of leukapheresis  
 Event duration  including  start date and end date, or if continuing at End of Treatment ( EOT ) 
or End of Study  (EOS ) visits  
 Action taken with  the IMP due to reported event (no action  taken; delay of further 
application; permanently discontinued; other ) 
 Action taken with first line chemotherapy due to reported event (no action taken; dose 
adjusted ; dose  interrupted ; delay  of further application; permanently discontinued ) 
 Other action taken (hospi[INVESTIGATOR_91536]; change in concomitant medication; medic al 
procedure or intervention required; other or unknown ). 
 Event seriousness (serious or non -serious) : a serious adverse event (SAE) is any untoward 
medical occurrence that at any dose fu lfills one or more of the following criteria : 
 Results in death.  
 Is immediately life-threatening .  
The term “life -threatening” in the definition of serious  refers to an event in which 
the patient was at immediate risk of death at the time of the event; it does not refer 
to an event which hypothetically might have caused death if it were more severe . 
 Results in persistent or significant disability/incapacity.  
 Is a congenital anomaly/birth defect.  
 CONFIDENTIAL  Protocol No . SP005  
  EudraCT: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page 63 of 96 
 
 Requires inpatient hospi[INVESTIGATOR_1081], unless 
hospi[INVESTIGATOR_062]:  
 Routine treatment or monitoring of the studied indication including 
hospi[INVESTIGATOR_781306] (e.g.  leukapheresis) not 
associated with any deterioration of patient´s status . 
 Elective or pre -planned treatment (prior to signing the informed consent form) 
for a pre -existing condition that is unrelated to the indication under study and 
has not worsened since signing the informed consent.  
 Treatment on an emergency outpatient basis for an event not fulfilling any of 
the definitions for an SAE  and not resulting in hospi[INVESTIGATOR_063].  
 Social reasons  and respi[INVESTIGATOR_781307]’s general condition.  
 Underlying disease progression and events which are unequivocally related to 
the disease progression.  
 Is other medically significant  event , i.e., defined as an event that may not be 
immediately life - threatening or result in death or hospi[INVESTIGATOR_781308].  
 
Hospi[INVESTIGATOR_417041] -patient overnight stay that can be shorter than [ADDRESS_1074117] special 
reporting requirements; see Section 8.1. 
 
If an AE (SAE) increases in severity, the event will be reported at the higher severity grade 
or frequency as a new AE (SAE). The onset date of the new AE will be the date that the 
severity  increased. A decrease in severity should not be reported as a new AE.  
 
All AEs should be acted upon. Such acts may include changes in study drug treatment including 
possible interruption or discontinuation, starting or stoppi[INVESTIGATOR_058], cha nges 
in the frequency or nature of assessments, hospi[INVESTIGATOR_059], or any other medically required 
intervention.  
 
AEs causally not related to the IMP / procedure will be monitored (followed -up) until 
resolution, stabilization (becoming permanent condition) or the end of the clinical trial. 
Clinically relevant laboratory abnormalities will be followed -up until they return to normal or 
become stabilized  (permanent condition) .  
 
Any AE which is or might be related to the IMP / procedure as well as all  SAEs will be 
followed -up until the event is resolved or stabilized  (permanent condition) .  
 
AE assessment should be made at each visit (or more frequently, if necessary) of any changes 
in diagnosis,  severity, suspected relationship to  the IMP, procedure  or first line chemotherapy,  
interventions required to treat the event , and its outcome.  
 CONFIDENTIAL  Protocol No . SP005  
  EudraCT: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page 64 of 96 
 
Information about adverse reactions (causally related events) already known for the 
investigational product can be found in the Investigator´s Brochure ( IB) or will be 
communicated between IB updates in the form of Dear Investigator  Letter . Basic information 
will be included in the patient informed consent and should be discussed with the patient during 
the study as needed.  
 
7.6.2 Physical examination, weight, heig ht 
Physical examinations will be performed by a licensed physician (or physician’s assistant or 
nurse practitioner) at screening.  Symptom -directed exams will be performed on Day [ADDRESS_1074118] of Care chemotherapy and each application of DCVAC /PCa or placebo until 
End of Treatment visit and may be performed by a licensed physician, NP, PA, or nurse . All 
examinations should assess the patient for clinical signs of autoimmune disease.  
 
Height in centimeters (cm) and body weight (to the nearest 0.1 kilogram [kg] in indoor clothing, 
but without shoes) should be measured at Screening, and weight will be measured at each dosing 
visit of Standard of Care chemotherapy during Concu rrent treatme nt period and at each 
DCVAC/PCa or placebo administration visit in the Maintenance Boosting period and at the End 
of Treatment Visit . 
 
7.6.3 Vital signs  
Vital signs ( body temperature, sitting blood pressure and sitting pulse) will be measured at 
Screening and at  each dose of Standard of Care chemotherapy and DCVAC/PCa or placebo as 
well as at End of Treatment Visit . 
Measurements of heart rate, body temperature, blood pressure and respi[INVESTIGATOR_781309] a minimu m of [ADDRESS_1074119] DCVAV/PCa or placebo 
administration and for 30 minutes following each subsequent administration.  
 
7.6.4 Performance status  
Eastern Cooperative Oncology Group (E COG)[ADDRESS_1074120] of C are chemotherapy 
and each injection of DCVAC/PCa or placebo  and at the End of  Treatment Visit . 
 
ECOG Performance status should be documented according to Table 2. 
  
 CONFIDENTIAL  Protocol No . SP005  
  EudraCT: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page 65 of 96 
 
Table 2: ECOG performance status scale  
 
Grade  ECOG  
0 Fully active, able to carry on all pre -disease performance without restriction.  
1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or 
sedentary nature, e.g. light house work, office work.  
2 Ambulatory and capable of all self -care but unable to carry out any work activities.  Up and about 
more than 50% of waking ho urs. 
3 Capable of only limited self -care, confined to bed or chair more than 50% of waking hours.  
[ADDRESS_1074121] clinical laboratory analysis described below is to be performed by a central 
laboratory according to the Visit Evaluation Schedule, outlined in Table 1 and will be 
documented in the eCRF.  Details on the  collections, shipment of samples and reporting of 
results by [CONTACT_781356] .  
 
More frequent evaluations may be performed at the Investigator’s discretion if medically 
indicated; results should be recorded on the Unscheduled Visit eCRFs.  Due to unanticipated 
circumstances, if at any time a patient has laboratory parameters obtain ed from a local 
laboratory, SOTIO must be provided with a copy of the certification and a tabulation of the 
normal ranges for that laboratory.  
  
Laboratory values that are out of reference ranges should be evaluated for their clinical 
significance. Abnormal laboratory values or test results that constitute AEs or underlying 
conditions should be recorded together with the respective AEs or underlying diagnosis.  Only  
laboratory abnormalities that are considered clinically significant  e.g. due to induct ion of 
clinical signs or symptoms, lead to a change in medication dosage or administration, requiring 
concomitant therapy , or other medical intervention (e.g. hypokalemia that need saline 
substitution or hematologic abnormality that requires  cytokine treatment) or require that the 
patient changes the study schedule should be recorded on the AE eCRF  page . Whenever 
possible, a diagnosis, rather than a symptom should be provided  on the AE eCRF  page  (e.g. 
anemia instead of low hemoglobin).  
 
It sho uld be noted that s everity and seriousness are different criteria  for AE evaluation . 
Therefore, g rade 3 and grade 4 laboratory events (evaluated as per NCI CTCAE v4.03 ) do not 
automatically classify as  SAE s unless  they meet serious ness criteria  as defined in section 7.6.1  
or as per Investigator’s discretion.   
 
 CONFIDENTIAL  Protocol No . SP005  
  EudraCT: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page 66 of 96 
 
[IP_ADDRESS]  Hematology  
Hematologic  tests include: a complete blood count (CBC) consisting of red blood cells (RBCs), 
a total WBC with differential (total neutrophil , lymphocyte, monocyte, eosinophil, and basophil 
counts), hemoglobin, hematocrit,  and platelet count s.  
 
Hematology  will be collected every 3 weeks (or Day 1 ( -3 days) of each chemotherapy cycle) 
during the Concurrent Treatment Period  with DCVAC/PCa or pla cebo and first line 
chemotherapy  with docetaxel  plus prednisone . Should first line chemotherapy be discontinued 
hematology  should continue to be collected every 4 weeks ( -7days /+14 days ) until the 
discontinuation of DCVAC/PCa or placebo.    
 
In the Follow -up period when the patient is no longer receiving DCVAC/PCa or placebo, 
hematology  will be collected once  at End of Treatment  Visit. More frequent evaluations may 
be performed at the Investigator’s discretion if medically indicated; results should be recorded 
on the Unscheduled Visit eCRFs.  
 
[IP_ADDRESS]  Coagulation  
Coagulation tests  (aPTT and Quick ) should be drawn at screening  for evaluation purposes to 
leukapheresis . 
 
[IP_ADDRESS]  Biochemistry  
Biochemistry includ es Na+, K+, Cl-, Ca2+, glucose, AST, ALT, ALP, LDH, b ilirubin, creatinine, 
uric acid, CRP, total protein, and albumin .  
 
Biochemistry will be collected every 3 weeks (or Day 1 ( -3 days) of each chemotherapy cycle) 
during the Concurrent Treatment Period  with DCVAC/PCa or placebo and first line 
chemotherapy  with docetaxel plus prednisone .  
Should first line chemotherapy be discontinued , biochemistry should continue to be collected 
every 4 weeks ( -7days /+14 days ) until the discontinuation of DCVAC/PCa or placebo.  
TSH will be obtained every 12 weeks.   
In the F ollow -up Period when the patient is no longer receiving DCVAC/PCa or placebo, 
biochemistry will be collected once at End of Treatment  Visit . More frequent evaluations may 
be performed at the Investigator’s discretion if medically indicated; results should be recorded 
on the Unscheduled Visit eCRFs.  
 
[IP_ADDRESS]  Urinalysis  
Urinalysis including dipstick analysis (pH, protein, glucose, ketones, bilirubin, blood, leucocyte  
esterase ) will be collected every 6 weeks (+/ -7 days)  during the Concurrent Treatment period 
and every 12 weeks  (-14/+7 days)  in Maintenance Boosting  period . 
In the Follow -up Period when the patient is no longer receiving DCVAC/PCa or placebo, 
urinalysis will be collected once at End of Treatment  Visit . A mi croscopic (WBC/high power 
field (HPF), RBC/HPF, and any additional findings) exam need only be performed if the 
urinalysis result is abnormal.  
 
 CONFIDENTIAL  Protocol No . SP005  
  EudraCT: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page [ADDRESS_1074122] administration of DCVAC/PCa or placebo.  
 
7.6.[ADDRESS_1074123] evidence of active disease and are directly 
excluded from t he study participation. Eligibility of patients with positive HBs Ab and/or anti -
HBc Ab, must be confirmed  with the medical monitor and leukapheresis center first. National 
and local guidance and regulations should be followed for HBV testing  (or clinically equivalent 
test). An additional test before leukapheresis may be required.  
 
Before  randomization subjects  will be tested for HCV  Ab and HCV  RNA -PCR test at Screening  
(depending on local regulations).  Subjects  with detectable HCV RNA at scre ening and evidence 
of active disease are not eligible.  National and local guidance and regulations should be 
followed for HCV testing. An additional test before leukapheresis may be required.  
 
Before  randomization subjects  will be tested for syphilis. Subjects with positive syphilis results 
at screening and evidence of active disease are excluded from the study.  Should the patient 
refuse testing, his participation will be terminated in the screening phase . National and local 
guidance and regulations should be followed for syphilis testing. An additional test before 
leukapheresis may be required.  
  
 
 
 
 CONFIDENTIAL  Protocol No . SP005  
  EudraCT: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page 68 of 96 
 
7.6.9 Cardiac examinations  
 
[IP_ADDRESS]  Electrocardiogram (ECG)  
There are no  required ECGs for this study. The Investigator should follow institutional 
guidelines and best clinical practice when assessing the suitability of the patient for 
leukapheresis procedure, and administration of trial treatment, including the assessment of 
cardiac function with ECGs.  
 
[IP_ADDRESS]  Cardiac imaging - MUGA (multiple gated acquisition) scan or 
echocardiogram  
The patient’s medical records should be reviewed for evidence of cardiac disease of myocardial 
infarction or ventricular arrhythmias or stroke within a 6 month period prior to inclusi on. This 
also includes known LVEF < 40% or serious cardiac conduction system disorders if a 
pacemaker is not present.  MUGA scans or echocardiograms are not required at baseline 
screening to rule out evidence of cardiac co -morbidity.  
 
7.[ADDRESS_1074124] -P and EQ -5D (EQ -5D only in Europe) will be utilized for this study (see 
Section 14.1). The questionnaire FACT -P will be completed by [CONTACT_781357], on Day 
[ADDRESS_1074125] chemotherapy and every 6 weeks during the Concurrent Treatment  period and 
every 4 weeks dur ing Maintenance  Boosting period, and at the End of Treatment  visit. The 
questionnaire EQ -5D will be completed by [CONTACT_781358], on Day 1 of Cycle 
3 of the Concurrent Treatment period and then every 12 weeks until disease progression (e.g. 
under ideal circumstances during the Concurrent Treatment period on Day 1 of Cycle 7, during 
the Maintenance Boosting period on Da y 1 of Cycle 1 and on Day 1 of Cycle 4, at the End of 
Treatment visit, and at visits during the Follow -up period). The questionnaire  EQ-5D will also 
be completed at [ADDRESS_1074126] of trial treatment or identify subjects  profiting from it. Blood samples for 
exploratory studies will be collected at Randomization, prior to the 5th dose of DCVAC/PCa or 
placebo, and at the End of Treatment Visit . Samples will be processed at the central lab and 
cryopreserved. Upon request, samples will be shipped to SOTIO facilities and analyzed.   
The list of planned exploratory immune response studies includes:  
 CONFIDENTIAL  Protocol No . SP005  
  EudraCT: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page 69 of 96 
 
- Monitoring of circulating tumor cells in the peripheral blood  
- Analysis of the immune cells subsets in the peripheral blood (myeloid dendritic cells, 
plasmacytoid dendritic cells, CD4 T cells, CD8 T cells, CD19 B cells, NK cells, 
activated  HLA -DR+ T cells)  
- Monitoring peripheral blood FoxP3+ regulatory T  
- Monitoring of myeloid derived suppressor cells  
- Quantification of tumor antigen specific T cells in the peripheral blood by [CONTACT_210563] -, IL-2 and TNF  
- Quantification of PSA, PSMA and NY -ESO1 specific CD8 T cells in the peripheral 
blood by [CONTACT_781359] -A2 positive subjects  
 
Genomic  studies may be performed, if the patient consented to participate in pharmacogenomic 
research. A separate patient information sheet  and/or consent form is to be presented to the 
patient. Consent to participate in pharmacogenomic research is optional and  not a prerequ isite 
for entry into the study.  
 
Peripheral blood samples will be used for the isolation of nucleic acids  (DNA or RNA). Purified 
genomic DNA (gDNA) will then be fragmented, and a gDNA library will be prepared. Region s 
of gDNA will be sequenced using appropriate next generation sequencing technique s. For the 
purpose of gene expression profiling the t otal RNA will be purified and reversely transcribed 
into the complementary DNA (cDNA).  cDNA will be used for gene expression profiling and 
for the detection of expression levels of potential cancer related genes. RNA samples can also 
be used as a template for RNA sequencin g technique s. 
 
The aim of the genomic studies is to identify any genetic alterations as well as new potential 
biomarkers that could be used for evaluation of risk of disease progression in patients with 
prostate cancer and for the identification of those p atients, who could benefit from cancer 
immunotherapy .  
 
Additional exploratory studies may be conducted based on the future advances in the field of 
biomarker research.  Performing of the above mentioned experimental studies is subject to the 
availability o f sufficient number of peripheral blood mononuclear cells from  subjects . 
Complete instructions for collection and processing will be provided in a study Laboratory 
Manual.  
 
Clinical signs of possible autoimmune disease will be assessed during each physical  exam. If 
there is any suspi[INVESTIGATOR_781310], appropriate 
laboratory evaluation should be performed at the Investigator’s discretion.  
 
 
  
 CONFIDENTIAL  Protocol No . SP005  
  EudraCT: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page [ADDRESS_1074127] immediately (at the latest within 24 hours of 
awareness ) notify / report to pharmacovigilance department all SAEs, regardless of suspected 
causality . All SAEs must be reported from the date of the patient  signing the informed consent 
form until [ADDRESS_1074128] administration of DCVAC/PCa or placebo (EOT).   
 
Recurrent epi[INVESTIGATOR_781311] [ADDRESS_1074129], and considers the event causally related  to the 
IMP, this event has to be reported within 24 hours of learning of its occurrence.  
 
Serious AE information is collected and recorded on the Serious Adverse Event (SAE) Report 
Form. The Investigator must complete the electronic SAE Report Form in Eng lish, and submit 
the completed and signed form via eCRF (EDC system) within [ADDRESS_1074130] details below:  
 
Fax:  [PHONE_16317] or local  toll free fax lines  
Email:  [EMAIL_14907]  
Phone:  [PHONE_16318]  
Address:  SOTIO a.s., Jankovcova 1518/2, [ADDRESS_1074131]: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page 71 of 96 
 
8.1.1   Serious  Adverse Events related to disease progression  
Progression of underlying dis ease or AEs unequivocally related to disease progression in line 
with the study protocol (see section 7.5), regardless of their outcome and regardl ess whether 
they otherwise would fulfill seriousness criteria, do not need to be reported as SAEs. However, 
these events have to be captured on AE eCRF page as non -serious events. If the patient was 
hospi[INVESTIGATOR_781312].  
 
An SAE must be reported only if there are clinical signs / symptoms that cannot be without 
doubt associated to the underlying disease progression.  
 
Events with fatal outcome that are unequivocally related to progression of underlying disease 
are excluded from SAE reporting and expedited reporting as S[LOCATION_003]Rs. Overall survival is the 
primary endpoint of the trial. Therefore, it is essential to complete the End of Study Information 
eCRF page to capture the death information. If a patient d ies due to the progression of 
underlying disease the EOS eCRF page should include the EOS reason as ‘Death’ and the cause 
of death must be reported as ‘Disease Progression’.  
8.1.[ADDRESS_1074132]’s ongoing safety and scientific monitoring 
are referred as AEs of Special Interest (AESIs). These events require ongoing monitoring and 
rapid communication by [CONTACT_68477].  
 
SAE report form is used for reporting of AESIs. AESI s have to be reported within the same 
timelines as SAEs. Further details are specified in relevant study manual.  
 
The following AESIs must be reported : 
1. Patient ’s premature discontinuation from the DCVAC/PCa or placebo treatment due to 
an AE (drop -out). 
2. Systemic a llergic reactions related to IMP administration (other than local inflammatory 
reaction or irritation at injection site ). 
3. Severe systemic i nfections related to IMP administration  (e.g. sepsis  due to transmission 
of infectious agents ). 
4. Secondary malignancy.  
5. Autoimmune disorder (only symptomatic / clinically relevant) . 
 
Only AESIs with plausible causal relationship to investigational product must be reported after 
[ADDRESS_1074133] IMP administration (EOT).  
8.1.[ADDRESS_1074134] administration of DCVAC/PCa  or placebo , the patient must inform their 
 CONFIDENTIAL  Protocol No . SP005  
  EudraCT: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page [ADDRESS_1074135] be collected for the female partners of 
any males administered DCVAC/PCa  or placebo . Consent to report information regarding these 
pregnancy outcomes should be obtained fro m the mother.  
 
Every new pregnancy of female partner of a study patient and the outcome of the pregnancy 
has to be reported via a ‘Pregnancy Data Collection Form’  (hard copy)  which must be submitted 
within 24 hours of learning of its occurrence using the s ame route and timelines as described 
for SAEs.  
 
 
8.2 Independent Data Monitoring Committee  
An independent Data Monitoring Committee ( IDMC) will be constituted prior to the 
randomization of the first patient.  It is expected that the IDMC will consist of five members 
including one statistician.  The IDMC will operate according to  IDMC Charter which will be 
developed prior to the start of the study.  The IDMC Charter will outline the data format and the 
process for all data tabulations that will be submitted to the IDMC for their review. The Charter 
will also  describe the roles and responsibilities of the IDMC members and the timing and scope 
of all IDMC meetings.   
 
The purpose of the IDMC will be to provide an independent mechanism for ongoing review of 
key a dverse events and SAEs . As will be noted in the IDMC Charter, all meetings of the IDMC 
will be confidential and there will be no data dissemination to sponsor representatives.  
In addition, the IDMC will monitor the DCVAC/PCa or placebo manufacturing failure rate in 
the context of the rate of lost to follow -up (LTF) subjects . The LTF rate is  assumed to be 3% 
for the study. Should the rate of LTF be higher than expected, the IDMC may suggest trial 
modifications.   
The IDMC may make these recommendations to SOTIO:  
 
 To continue the trial as planned without modification (e.g. no safety issues, ethical to 
continue the trial as planned).  
 To continue the trial with modification (e.g. ethical to continue the study but 
recommen d an amendment to the protocol or incorporate an additional safety interim 
analysis before the next scheduled analysis).  
 To halt enrollment pending discussions with SOTIO . 
 To stop the trial (e.g. serious safety concerns precluding further study treatment).  
 
If the study is recommended to continue by [CONTACT_781360] , no details about the results of the 
current analysis will be revealed until the end of the study.  
 
  
 CONFIDENTIAL  Protocol No . SP005  
  EudraCT: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page 73 of 96 
 
9 DATA REVIEW AND DATA MANAGEMENT  
 
9.1 Site Monitoring  
Before study initiation, at a Site Initiation Visit  (SIV) or at an Investigator’s meeting, SOTIO 
personnel (or designated CRO) will review the protocol and eCRFs with the Investigators and 
their staff.  During the study, the field monitor will visit the site regularly to check the 
completeness of patient re cords, the accuracy of entries on the eCRFs, the adherence to the 
protocol and to Good Clinical Practice (GCP), the progress of enrollment, and to ensure that 
study drug is being stored, dispensed, and accounted for according to specifications.  Key study 
personnel must be available to assist the field monitor during these visits.  
 
The Investigator must maintain source documents for each patient in the study recruited at the 
relevant site, consisting of case and visit notes (hospi[INVESTIGATOR_781313] s) containing 
demographic and medical information, laboratory data, and the results of any other tests or 
assessments.  All information on eCRFs must be traceable to these source documents in the 
patient's file.  The Investigator must also keep the original ICF signed by [CONTACT_102] (a second  
signed copy original is given to the patient).  
 
The Investigator must give the monitor access to all relevant source documents to confirm their 
consistency with the eCRF entries. SOTIO monitoring standards require full v erification for the 
presence of informed consent, adherence to the inclusion/exclusion criteria, documentation of 
SAEs, and the recording of data that will be used for all primary and safety variables.  Additional 
checks of the consistency of the source dat a with the eCRFs are performed according to the 
study -specific monitoring plan.  No information in source documents about the identity of the 
subjects  will be disclosed.  
 
9.2 Data Collection  
For studies using EDC, the designated Investigator site staff will enter the data required by [CONTACT_781361] 21 CFR Part 11 and 
EMA/INS/GCP/454280/[ADDRESS_1074136] bee n trained.  Automatic validation programs check 
for data discrepancies in the eCRFs and, by [CONTACT_105273], allow 
modification or verification of the entered data by [CONTACT_781362] (or designat ed CRO).  After database lock, the Investigator will receive a CD -ROM 
or paper copi[INVESTIGATOR_314192].  
 
9.3 Database Management and Quality Control  
Data will be entered into the study database by [CONTACT_737]/St udy Coordinator at each site.  
 
SOTIO personnel (or designated CRO) will review the eCRFs entered by [CONTACT_781363].  Queries are sent to the i nvestigational site within the EDC system . Designated 
Investigator site staff is required to respond to the query and make any necessary changes to the 
data. If the electronic query system is not used, a paper DQF will be faxed to the site.  Site 
 CONFIDENTIAL  Protocol No . SP005  
  EudraCT: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page 74 of 96 
 
personnel  will complete and sign the faxed copy and fax it back to SOTIO Data Management 
personnel (or designated CRO) who will make the correction to the database if required. In 
addition the signed original and resolved DQFs must also be sent to SOTIO Data Manage ment 
(or designated CRO). Copi[INVESTIGATOR_781314]. 
 
Concomitant medications entered into the database will be coded using the World Health 
Organization (WHO) Drug Reference List, which employs the Anatomic al Therapeutic 
Chemical classification system.  Medical history/current medical conditions and AEs will be 
coded using the Medical Dictionary for Regulatory Activities (MedDRA) terminology.  Central 
laboratory samples and/or data will be processed centrally and the results will be sent 
electronically to SOTIO (or a designated CRO).  
 
Randomization codes and data about all study drug dispensed to the patient will be tracked 
using an IVRS/IWRS.  The system will be supplied by a vendor(s), who will also manage the  
database.  The database will be sent electronically to SOTIO personnel (or designated CRO).  
 
At the conclusion of the study, the occurrence of any protocol violations will be determined.  
After these actions have been completed and the database has been dec lared to be complete and 
accurate, it will be locked.   
 
 
  
 CONFIDENTIAL  Protocol No . SP005  
  EudraCT: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page 75 of 96 
 
10 STATISTICAL METHODS AND DATA ANALYSIS  
The details of the statistical analyses to be performed on the collected data will be described in 
a separate Statistical Analysis Plan.  This statistical considerations section is focused on the 
primary analysis.  
 
10.1 Analysis Populations  
There are 4 analysis populations.  The definitions and criteria provided hereinafter will be 
updated and possibly detailed in the Statistical Analysis Plan during the data revi ew. 
 
All Randomized Subjects (ARS)  
The ARS is a set of subjects  who entered the study and who were randomized.  The ARS will 
be used for a summary of demographic and other baseline characteristics.  
 
Safety Population  
The Safety population  will comprise all subjects who received first-line chemotherapy and/or 
at least one dose of treatment with DCVAC/PCa or placebo  and will be based on the actual 
treatment received if this differs from that to which the subject was randomized.  This populati on 
will be used for the analysis of safety data.  
 
Intent -to-Treat Population (ITT)  
The ITT population is a subset of all randomized subjects  who had at least one baseline 
assessment. ITT will be the primary efficacy population.  
 
ITT subjects  will be analy zed according to their randomized  study medication.  
 
According to Section 6.10 patients will be withdrawn from treatment, or not receive treatment, 
due to:  
 Emergency unblinding of treatment assignment when investigator or patient  are 
unblinded.  
 Protocol violation requiring patient withdrawal as assessed by [CONTACT_425826].  
 Patient unable to tolerate the leukapheresis procedure . 
 Failure to produce DCVAC/PCa or placebo in the Sponsors manufacturing facilities.  
 Patients having a serious allergic reaction t o DCVAC/PCa or placebo must be 
withdrawn from the treatment phase of the study.  
 
Patients with emergency unblinding and patients with protocol violations will be included in 
the ITT population and analyzed accordingly. P atients who have not started DCVAC/PCa or 
placebo treatment due to leukapheresis or manufacturing failure  will also be in clude d in the 
ITT population, however censor ed on Day [ADDRESS_1074137]: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page 76 of 96 
 
Per Protocol Population (PP)  
The PP population is a subset of the ITT and includes all subjects  who are characterized  by 
[CONTACT_12294]:  
 
 All subjects who have at least one post baseline assessment.  
 All subjects who do not have any major protocol violations that would affect the 
endpoints being assessed.  
 All subjects randomized to a treatment who received at least eight  doses of 
DCVAC/PCa or p lacebo .  
 Any other criterion as deemed appropriate will be listed in the Statistical Analysis 
Plan.  
 
The m ajor protocol violations and detailed reasons for excluding subjects from per protocol set 
will be fully defined and documented before breaking the blind of the specific trial.  PP 
population will be analy zed according to their actual study medication.  The PP population is 
the secondary efficacy population.  
 
10.1.[ADDRESS_1074138] received a different dose of a study medication than that planned in the study 
protocol will be listed including in formation on all doses actually received.  
 
Concomitant medications will be coded using the current WHO Drug Dictionary.  The number 
and percentage of subjects  who used concomitant medications will be presented by [CONTACT_781364] (ATC) levels 1 an d 2 and by [CONTACT_1570].  
 
10.2 Primary Efficacy Analysis  
 
10.2.1  Primary Efficacy Endpoint  
Survival time, defined as the time from randomization until death due to any cause, is the 
primary endpoint. The primary efficacy analysis will be done with the ITT population.  
 
10.2.2  Statistical Hypothesis, Model and Method of Analysis  
The primary endpoint in this study is OS .  
 
The primary hypothesis testing is to demonstrate that the treatment with DCVAC/PCa in 
addition to Standard of Care chemotherapy (docetaxel plus prednisone) is statistically 
significantly different from the treatment of Standard of Care chemotherapy (docetaxel plus 
prednisone) versus the null hypothesis of no difference between two treatment ar ms. 
 
 CONFIDENTIAL  Protocol No . SP005  
  EudraCT: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page [ADDRESS_1074139] . Assuming an exponential distribution, 
a total of 657  deaths is required with approximately 80% power to detect a hazard ratio of 0.792 
in favor of the DCVAC/PCa group (median survival of 24 months for the DCVAC/PCa group, 
19 months for the control group) using a [ADDRESS_1074140] at a 5% overall significance level 
(i.e. alpha of 0.05).  A total of 1170  patients will be enrolled in a 2:1  ratio (i.e., DCVAC/PCa vs. 
placebo equal to 2:1), an enrollment period of approximately 18 months, and total study 
duration of approximately 40 months to observe the required event -driven timeframe of 657 
total events for the final analysis.  If the anticipated 657 events are not attained during the trial 
timeline, the study could be prolonged by [CONTACT_781365].  
 
Patients will be randomized in a 2:1 ratio, stratified by [CONTACT_11338] (US vs other ), prior therapy 
(abiraterone or enzalutamide or neither of the two ) and ECOG score (0, 1 vs 2). 
 
The overall type I error rate will be controlled at 0.05.  At the final analysis , a final p -value of ≤  
0.0455 is required to be considered statistically significant.  (East 5.4 software with ‘Null’ 
variance was used for total events and statistical significance boundary determination ).  
 
A Kaplan -Meier plot of survival by [CONTACT_781366].  Censored observations will be indicated 
on the Kaplan -Meier plot. Tabular summaries of the Kaplan -Meier analysis giving the median, 
quartiles, minimum and maximum will be displayed.  
 
The hazard ratio  and its 95% confidence interval will be estimated using the Cox proportional 
hazard regression model with the same stratification factors as used in the log rank test.  
 
The following sensitivity analyses of the primary endpoint will be also performed usin g the 
ITT population:  
o Unstratified Log rank test and Cox model (No stratification and prognostic factors 
adjustment).  
o To analyze the effects of imbalance in the baseline characteristics and treatment 
with chemotherapy by [CONTACT_781367]. In addition to treatment and the 3 stratification factors, 
the followin g prognostic factors16,33 will be included in the model simultaneously:  
Baseline PSA (values will be log transformed before  inclusion, if any values = [ADDRESS_1074141] 1 added before  transformation to allow  for all values to be 
included after transformation), baseline LDH (> ULN; ≥ ULN) (1/0), baseline 
ALP (values will be log transformed before  inclusion), baseline albumin, baseline 
hemoglobin, Gleason score 2 -7; 8-10) at initial diagnosis (1/0), opi[INVESTIGATOR_2441] (yes ; 
no) (1/0), disease site (will be defined in a separate document). This will be done 
on the ITT population.  
 
Log transformation of covariates may be used in the model. The adjusted hazard ratio and its 
two-sided 95% confidence interval will be estimated u sing the Cox proportional hazard 
regression model with the covariates.  
 
 CONFIDENTIAL  Protocol No . SP005  
  EudraCT: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page [ADDRESS_1074142] secondary therapy will be added as time -dependent covariate to the a bove 
primary Cox model.  
 
A separate summary of survival  data will be provided for patients with leukapheresis or 
manufacturing failure.  A sensitivity analysis  including  the real survival data of patients with 
leukapheresis or manufacturing failure  as such (and not censored on Day 1) , will be 
performed  to show robustness of the primary analysis . Such  sensitivity analysis is indeed 
more conservative and could potentially show lower treatment effect. It will be conducted 
with an intention to show that the resu lts of the primary analysis are robust enough and their 
interpretability is not jeopardized.  
Additional exploratory analyses may be performed if deemed necessary.  
 
10.2.[ADDRESS_1074143] sk eletal 
related events and time to radiographic progression or SRE will be also analy zed. 
 
Incidence of skeletal related events (SRE) will be summarized.  
 
Definitions of endpoints reflect recommendations of PCWG229 (see section 7.3). For Soft tissue 
and Bone evaluations there will be Investigator based and IRF results . Both results to be 
recorded, but the IRF conclusion will be used for ultimate evaluation  as specified in the trial 
specific Imaging Charter . Radiographic assessments by [CONTACT_781368] . 
  
A fixed sequential testing procedure will be used to test the [ADDRESS_1074144]: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page 79 of 96 
 
up will vary between subjects . Consequently, there will be no imputation for missing data.  For 
time-to-event endpoints (e.g. time to rPFS,  time to PSA progression  and time to SRE ), the last 
date of documented disease status will be used if event (progression) had not been documented 
at the time of the analysis or subjects had withdrawn the study prior to determination of 
progression; such subjects will be considered cen sored in the analysis.  
  
10.3.2  Safety  
 
[IP_ADDRESS]  Adverse events  
AEs will be coded using MedDRA and grouped by [CONTACT_1196].  AE severity will be 
graded according to NCI CTCAE 4.03.  An AE is considered treatment -emergent when the onset 
date of the event falls on or after the earliest start date of chemotherapy or study treatment and 
when the onset date of the event occurs until [ADDRESS_1074145] dose given (first line chemo 
or study treatment) or when the AE worsens (increase in severity and/or frequency) on or after 
the earliest start date of chemotherapy or study treatment . Only treatment -emergent AEs 
occurring from the first dose through [ADDRESS_1074146] dose of study treatment will be 
summarized.  
 
AEs will be classified according to severity and relati onship to study medication.  
 
The number and percentage of subjects  who experienced any treatment -emergent: AE, SAE, 
treatment related AE  and treatment related SAEs, will be summarized.  The denominator used 
to calculate incidence percentages consists of subjects in the Safety Population. Incidence of 
safety complications resulting from leukapheresis will also be reported in the analysis of safety.  
 
AEs will be grouped by [CONTACT_781369].  For tables by [CONTACT_210079], if a patient has more than one 
AE the maximum grade will be summarized.  
 
Missing values will be treated as missing, except for causality of AEs to study drugs. If causality 
is missing, the AE will be regarded as rela ted to study drug.  
 
[IP_ADDRESS]  Laboratory  
Clinical laboratory parameters will be used for individual patient safety monitoring.  Laboratory 
values will be graded according to the NCI CTCAE 4.03.  For each patient the baseline value is 
the value recorded at screening . The actual laboratory values and changes from baseline will be 
summari zed by [CONTACT_443228].  
 
Laboratory abnormalities will be identified, summarized and presented in shift tables for each 
Study Cycle (baseline [Cycle 1, Day 1 pre -dose] versus Study  Cycle toxicity grade) and by 
[CONTACT_781370] (baseline versus worst toxicity grade across all visits ). 
 
 CONFIDENTIAL  Protocol No . SP005  
  EudraCT: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page 80 of 96 
 
[IP_ADDRESS]  Other safety data  
Physical examination findings will be captured at baseline and during the Treatment Period and 
abnormalities that represent a worsening or change from baseline will be reported as AEs.  
  
Vital signs will be summarized as measured values during the study and as change and 
percentage change from baseline to final visit.  
 
Body weight will be summarized as change and percentage chang es from baseline to final visit.  
 
10.4 Exploratory Endpoints  
 
10.4.1  Quality of Life (QoL)  
Patient reported outcomes will include evaluation of QoL using the questionnaires FACT -P and 
EQ-5D (EQ -5D only in Europe) . The QoL questionnaires FACT -P and EQ -5D will be 
summarized by [CONTACT_781371]. Each score will be 
summarized by [CONTACT_781372]. Changes from baseline will be summarized and at 
specified time points  of interest by [CONTACT_6660].   
 
Missing values r elated to patient reported outcomes will be treated in accord ance with the 
appropriate scoring manual whenever possible.  If it is not possible, the Last Observation Carried 
Forward (LOCF) imputation technique may be used.  
 
10.4.2  Second Line Treatment  
Proportion of subjects  requiring second line  antineoplastic  treatment introduction will be 
summarized. Time from randomization to second line treatment initiation will be described.   
 
10.5 Pharmacokinetics  
Not applicable.  
 
10.6 Immune Response Biomarkers  and Gene Expressions  
See section 7.10 for description of these exploratory studies . 
 
10.7 Sample Size Calculation  
Sample size (in terms of number of deaths) calculation assumptions:  
 
 A median survival of 24 months for the DCVAC/PCa group, 19 months for the control 
group and an exponential survival.7,8 
 
 Subjects were randomized into the study with 2:1 allocation ratio (i.e., DCVAC/PCa: 
placebo equal to 2:1).  
 
 Assume an exponential survival distribution, then hazard ratio can be calculated as 
HR = MR/MT, where M T and M R are the median survival times on test and ref erence, 
respectively, which results in HR  = 0.792 in favor of the DCVAC/PCa group.   
 CONFIDENTIAL  Protocol No . SP005  
  EudraCT: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page 81 of 96 
 
 
 Assuming proportional hazards  
 
 Two-tailed level of significance of 0.05 and 80% power,  
 
Based on the above assumptions, the sample size (in terms of number of deaths)  would be 657 
events in total.  
 
To reach 657 events required, a total of 1170  patients will be enrolled in a 2:1  ratio (i.e., 
DCVAC/PCa vs. placebo equal to 2:1) with an expected enrollment period of approximately 18 
months, and total study duration of app roximately 40 months to observe the required event -
driven timeframe of 657 total events for the final analysis.  If the anticipated 657 events are not 
attained during the trial timeline, the study could be prolonged by [CONTACT_781365].  
 
Patients will be randomized in a 2:1 ratio, stratified by [CONTACT_11338] (US vs Other), prior therapy 
(abiraterone or enzalutamide or neither of the two ) and ECOG Score (0,  1 vs 2). 
 
The overall type I error rate will be controlled at 0.05.   
  
 CONFIDENTIAL  Protocol No . SP005  
  EudraCT: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page 82 of 96 
 
11 ADMINISTRATIVE PROCEDURES  
 
11.1 Regulatory and Ethical Compliance  
This clinical study was designed and shall be implemented and reported in accordance with the 
protocol, the ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable 
local regulations (in cluding European Directive 2001/20/EC and US Code of Federal 
Regulations Title 21), and with the ethical principles laid down in the Declaration of Helsinki.  
 
11.[ADDRESS_1074147] the right to 
review the terms and conditions described therein.  
 
11.3 Responsibilities of the Investigator and IRB/IEC  
The protocol and the proposed ICF must be reviewed and approved by a properly constituted 
Institutional Review Board/Independent Ethics Committee (IRB/IE C) before study start.  A 
signed and dated statement that the protocol and informed consent have been approved by [CONTACT_5040]/IEC must be given to SOTIO before study initiation.  Prior to study start, the Investigator 
is required to sign a protocol signature [CONTACT_550092] e confirming his agreement to conduct the study in 
accordance with these documents and all of the instructions and procedures found in this 
protocol and to give access to all relevant data and records to SOTIO monitors, auditors, SOTIO  
Clinical Quality Ass urance representatives, designated agents of SOTIO, IRBs/IECs and 
regulatory authorities as required.  
 
Where applicable by [CONTACT_781373], which has been  previously agreed by [CONTACT_276983]/IEC , containing as minimum the name [CONTACT_81835], the investigator 
contact [CONTACT_781374].  
 
Blood samples are being collected and stored for resear ch purposes for this study. The sponsor 
of the trial, the tissue establishments/procurement organization, the manufacturer and the 
investigator institution should keep their parts of the traceability records for a minimum of [ADDRESS_1074148], or longer if required by [CONTACT_781375]. In the case of the tissue establishments, if 
that period is longer than provided in the Directives referred to in section 3, the sp onsor should 
ensure through contractual agreements that the traceability records are kept for that longer 
period.  
 
11.4 Informed Consent  
Eligible subjects  may only be included in the study after providing written (witnessed, where 
required by [CONTACT_6617]), IRB/IEC -approved informed consent, or, if incapable of doing 
 CONFIDENTIAL  Protocol No . SP005  
  EudraCT: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page 83 of 96 
 
so, after such consent has been provided by a legally acceptable representative of the  patient.  
In cases where the patient’s representative gives consent, the patient should be informed about 
the study to the extent possible given his understanding.  If the patient is capable of doing so, he 
should indicate assent by [CONTACT_781376] a separate assent form. Informed consent must be obtained before conducting any study -
specific procedures (i.e. all of the procedures described in the protocol).  The process of 
obtaining informed consent shou ld be documented in the patient source documents.  
 
SOTIO will provide to Investigators in a separate document a proposed informed consent form 
that complies with the ICH GCP guideline and regulatory requirements and is considered 
appropriate for this study . Any changes to the proposed consent form suggested by [CONTACT_781377]/IEC, and a copy of the 
approved version must be provided to the SOTIO monitor after IRB/IEC approval.  
 
11.[ADDRESS_1074149] be approved by [CONTACT_781365], Health Authorities where required, and the IRB/IEC.  Only 
amendments that are required for patient safety may be implemented prior to IRB/IEC approval.  
Notwithstanding the need for approval of formal prot ocol amendments, the Investigator is 
expected to take any immediate action required for the safety of any patient included in this 
study, even if this action represents a deviation from the protocol.  In such cases, SOTIO should 
be notified of this action a nd the IRB/IEC at the study site should be informed within 10 
working days.  
 
11.7 Discontinuation of the Study  
SOTIO reserves the right to discontinue this study under the conditions specified in the clinical 
trial agreement.  
 
11.8 Study Drug Supply and Re -supply, S torage and Tracking/Drug 
Accountability  
Study drugs must be received by a designated person at the study site, handled and stored safely 
and properly, and kept in a secured location to which only the Investigator and designated 
assistants have access.  Upon  receipt, the DCVAC/PCa  or placebo should be stored according 
to the instructions specified on the secondary package labels.  Clinical supplies are to be 
dispensed only in accordance with the protocol.  
 
Medication package labels will comply with the legal requirements of each country.   
 
 CONFIDENTIAL  Protocol No . SP005  
  EudraCT: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page [ADDRESS_1074150]: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page [ADDRESS_1074151] be 
considered a protocol amendment, and unle ss such an amendment is agreed upon by [CONTACT_781378]/IEC and concerned regulatory authorities, it cannot be implemented.  
All significant protocol deviations will be recorded and reported in the Clinical Study Report.  
  
 CONFIDENTIAL  Protocol No . SP005  
  EudraCT: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page 86 of 96 
 
13 REFERENCES (available  upon request)  
 
1. Fact Sheets by [CONTACT_495752]. 2016; http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx . Accessed 
July 8, 2016.  
2. Center MM, Jemal A, Lortet -Tieulent J, Ward E, Ferlay J, Brawley O, Bray F. International 
Variation in Prostate Cancer Incidence and Mortality Rates. European Urology. 
2012;61(6):1079 -1092.  
3. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA: a  cancer journal for clinicians. 
2012;62(1):10 -29. 
4. American Cancer Society. Cancer Facts & Figures 2013. Atlanta: American Cancer Society. 
2013.  
5. Brawley OW. Prostate cancer epi[INVESTIGATOR_167491]. World Journal of Urology. 
2012;30(2):[ADDRESS_1074152] Sheets. 2015; 
http://seer.cancer.gov/statfacts/html/prost.html . Accessed March 09, 2015.  
7. Hochberg Y. A sharper Bonferroni procedure for multip le tests of significance. Biometrika. 
1988;75(4):800 -802. 
8. Guidelines on Prostate Cancer of the European Association of Urology. Uroweb   
http://uroweb.org/guideline/prostate -cancer/ . Accessed N ovember 19, 2015.  
9. Lu-Yao GL, Yao SL. Population -based study of long -term survival in patients with clinically 
localised prostate cancer. Lancet. 1997;349(9056):906 -910. 
10. Spi[INVESTIGATOR_781315] R, Dhodapkar MV. Immunoprevention of cancer. Hematology/Oncology Clinics of 
North America. 2006;20(3):735 -750. 
11. Fuessel S, Meye A, Schmitz M, Zastrow S, Linné C, Richter K, Löbel B, Hakenberg OW, Hoelig 
K, Rieber EP, Wirth MP. Vaccination of hormone -refractory prostate cancer patients with 
peptide cocktail -loaded dendritic c ells: Results of a phase I clinical trial. The Prostate. 
2006;66(8):811 -821. 
12. Drake CG, Antonarakis ES. Update: Immunological Strategies for Prostate Cancer. Current 
Urology Reports. 2010;11(3):202 -207. 
13. Slovin S. Chemotherapy and immunotherapy combi nation in advanced prostate cancer. Clinical 
Advances in Hematology & Oncology: H&O. 2012;10(2):90 -100. 
14. Rozkova D, Horvath R, Bartunkova J, Spi[INVESTIGATOR_781315] R. Glucocorticoids severely impair differentiation 
and antigen presenting function of dendritic cells des pi[INVESTIGATOR_781316] -like receptors. 
Clinical Immunology (Orlando, Fla.). 2006;120(3):[ADDRESS_1074153]'ovicka J, Podrazil M, Ulcová H, Budínský V, Prausová 
J, Linke Z, Minárik I, Sedivá A, Spísek R, Bartůnková J. FO CUS on FOCIS: combined chemo -
immunotherapy for the treatment of hormone -refractory metastatic prostate cancer. Clinical 
Immunology (Orlando, Fla.). 2009;131(1):1 -10. 
16. Halabi S. Prognostic Model for Predicting Survival in Men With Hormone -Refractory 
Metastatic Prostate Cancer. Journal of Clinical Oncology. 2003;21(7):[ADDRESS_1074154] S, Théodore C, James 
ND, Turesson I, others. Docetaxel plus prednisone or mitoxantrone plus prednisone for 
advanced prostate cancer. New England Journal of Medicine. 2004;351(15):1502 -1512.  
18. Serpa Neto A, Tobias -Machado M, Kaliks R, Wroclawski ML, Pompeo ACL, Del Giglio A. 
Ten Years of Docetaxel -Based Therapi[INVESTIGATOR_781317]: A Systematic Review 
and Meta -Analysis of 2244 Patients in 12 Randomized Clinical Trials. Clinical Genitourinary 
Cancer. 2011;9(2):[ADDRESS_1074155]: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page 87 of 96 
 
19. Cheever MA, Higano CS. PROVENGE (Sipuleucel -T) in Prostate Cancer: The First FDA -
Approved Therapeutic Cancer Vaccine. Clinical Cancer Research: Official Journal of the 
American Association for Cancer Research. 2011;17(11):[ADDRESS_1074156] 
cancer patients completing taxane treatment. Clinical Cancer Research: An Official Journal of 
the American Association for Cancer Research. 2004;10(10):3401 -3409.  
21. Kodumudi KN, Woan K, Gilvary DL, Sahakian E, Wei S, Djeu JY. A no vel 
chemoimmunomodulating property of docetaxel: suppression of myeloid -derived suppressor 
cells in tumor bearers. Clinical Cancer Research: An Official Journal of the American 
Association for Cancer Research. 2010;16(18):4583 -4594.  
22. Zitvogel L, Galluzz i L, Smyth MJ, Kroemer G. Mechanism of action of conventional and 
targeted anticancer therapi[INVESTIGATOR_014]: reinstating immunosurveillance. Immunity. 2013;39(1):74 -88. 
23. Galluzzi L, Senovilla L, Zitvogel L, Kroemer G. The secret ally: immunostimulation by 
[CONTACT_781379] r drugs. Nature Reviews. Drug Discovery. 2012;11(3):215 -233. 
24. Arlen PM, Gulley JL, Parker C, Skarupa L, Pazdur M, Panicali D, Beetham P, Tsang KY, 
Grosenbach DW, Feldman J, others. A randomized phase II study of concurrent docetaxel plus 
vaccine versus vaccine alone in metastatic androgen independent prostate cancer. Clinical 
Cancer Research. 2006;12(4).  
25. Antonia SJ. Combination of p53 Cancer Vaccine with Chemotherapy in Patients with Extensive 
Stage Small Cell Lung Cancer. Clinical Cancer Research. 2006;12(3):878 -887. 
26. Gribben JG, Ryan DP, Boyajian R, Urban RG, Hedley ML, Beach K, Nealon P, Matulonis U, 
Campos S, Gilligan TD, others. Unexpected association between induction of immunity to the 
universal tumor antigen CYP1B1 and response to next ther apy. Clinical Cancer Research. 
2005;11(12):4430 -4436.  
27. Spi[INVESTIGATOR_781315] R. Immunoprevention of cancer: time to reconsider timing of vaccination against cancer. 
Expert Review of Anticancer Therapy. 2006;6(12):[ADDRESS_1074157] to die with chemotherapy: role of heat shock 
protein exposure on dying tumor cells. Cell Cycle (Georgetown, Tex.). 2007;6(16):1962 -1965.  
29. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, 
Higano C, Bubley GJ, Dreic er R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small 
EJ, Beer TM, Wilding G, Martin A, Hussain M. Design and End Points of Clinical Trials for 
Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: 
Recommendations of the P rostate Cancer Clinical Trials Working Group. Journal of Clinical 
Oncology: Official Journal of the American Society of Clinical Oncology. 2008;26(7):1148 -
1159.  
30. NCCN Clinical Practice Guidelines in Oncology.  
http://www.nccn.org/professionals/physician_gls/f_guidelines.asp . Accessed March 09, 2015.  
31. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, 
Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. 
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). 
European Journal of Cancer (Oxford, England: 1990). 2009;45(2):228 -247. 
32. Oken MM, Creech RH, Tormey DC, Hort on J, Davis TE, McFadden ET, Carbone PP. Toxicity 
and response criteria of the Eastern Cooperative Oncology Group. American Journal of Clinical 
Oncology. 1982;5(6):[ADDRESS_1074158] -Line Chemotherapy for Patients With 
Metastatic Castration -Resistant Prostate Cancer. Journal of Clinical Onco logy. 2014;32(7):[ADDRESS_1074159]: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page [ADDRESS_1074160] -P Questionnaire  
 
Sample form and background available at:  http://www.facit.org/FACITOrg/Questionnaires  . 
For study purposes official forms will be distributed for completion by [CONTACT_1766].  
 
 

 CONFIDENTIAL  Protocol No . SP005  
  EudraCT: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page [ADDRESS_1074161]: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page [ADDRESS_1074162]: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page [ADDRESS_1074163]: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page [ADDRESS_1074164]: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page [ADDRESS_1074165]: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page [ADDRESS_1074166]: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page 95 of 96 
 
14.3 NCI CTCAE  
 
Version 4.03 of the National Cancer Institute (NCI) Common Terminology Criteria for Adverse 
Events (CTCAE), dated 14 June 2010 , may be viewed and/or downloaded by [CONTACT_781380]:   
 
http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010 -06-14_QuickReference_5x7.pdf  
 
  
14.4 Protocol Violations/Deviations  
http://www.genome.gov/Pages/Research/Intramural/IRB/Deviation_Violation_examples8 -07.pdf  
 
 
NIH IRB Professional Administrators Committee Version 5.1  
Regulatory Process Workgroup 1 11/18/2005  
 
Protocol Deviations and Violations  
Protocol Deviation - A protoco l deviation is any change, divergence, or departure from the 
study design or procedures of a research protocol that is under the Investigator’s control and 
that has not been approved by [CONTACT_1201]. Upon discovery, the Principal Investigator [INVESTIGATOR_781318].  Any change, 
divergence, or departure from the study design or procedures of a research protocol that affects 
the subject's rights, safety, or well-being  and/or the completeness, accuracy and reliability of 
the study data constitutes a protocol violation. Changes or alterations in the conduct of the trial 
which do not have a major impact on the subject's rights, safety or well -being, or the 
completeness, a ccuracy and reliability of the study data are considered minor protocol 
deviations.  
 
Protocol Violation - A protocol violation is a deviation from the IRB approved protocol that 
may affect the subject's rights, safety, or well-being  and/or the completeness,  accuracy and 
reliability of the study data.  If the deviation meets any of the following criteria, it is considered 
a protocol violation.  
 
Example list is not exhaustive.  
I. The deviation has harmed or posed a significant or substantive risk of harm to the  
research subject.  
Examples:  
• A research subject received the wrong treatment or incorrect dose.  
• A research subject met withdrawal criteria during the study but was not withdrawn.  
• A research subject received an excluded concomitant medication.  
 
 
II. The deviation compromises the scientific integrity of the data collected for the study.  
Examples:  
• A research subject was enrolled but does not meet the protocol's eligibility criteria.  
 CONFIDENTIAL  Protocol No . SP005  
  EudraCT: 2012 -002814 -38 
 
Oncology Clinical Trial Protocol  
(Version No. 07.0, Final, 08Mar 2018)  Page 96 of 96 
 
• Failure to treat research subjects per protocol procedures that spe cifically relate to primary 
efficacy outcomes. (if it involves patient safety it meets the first category above)  
• Changing the protocol without prior IRB approval.  
• Inadvertent loss of samples or data.  
NIH IRB Professional Administrators Committee Versio n 5.1  
Regulatory Process Workgroup 2 11/18/[ADDRESS_1074167] protection regulations, 
policies, or procedures on the part of the Investigator(s).  
Examples:  
• Failure to obtain informed consent prior to initiation of study -related procedures  
• Falsifying research or medical records.  
• Performing tests or procedures beyond the individual's professional scope or privilege status 
(credentialing)  
 
IV. The deviation involves a serious or continuing noncomplian ce with federal, state, local 
or institutional human subject protection regulations, policies, or procedures.  
Examples:  
• Working under an expi[INVESTIGATOR_739357]  
• Failure to follow federal and/or local regulations, and intramural re search or CC policies  
• Repeated minor deviations.  
 
V. The deviation is inconsistent with the NIH Human Research Protection Program’s 
research, medical, and ethical principles.  
Examples:  
• A breach of confidentiality.  
• Inadequate or improper informed consent procedure.  
 
Minor Protocol Deviation - A minor protocol deviation is any change, divergence, or departure 
from the study design or procedures of a research protocol that has not been approved by [CONTACT_781381] a major impact on the subject's rights, safety or well -being, 
or the completeness, accuracy and reliability of the study data.  
 
 